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Biological functions of antibiotics are not limited to killing. The most likely function of
antibiotics in natural microbial ecosystems is signaling. Does this signaling function of
antibiotics also extend to the eukaryotic – in particular mammalian – cells? In this review,
the host modulating properties of three classes of antibiotics (macrolides, tetracyclines,
and β-lactams) will be brieﬂy discussed. Antibiotics can be effective in treatment of a broad
spectrum of diseases and pathological conditions other than those of infectious etiology
and, in this capacity, may ﬁnd widespread applications beyond the intended antimicrobial
use. This use, however, should not compromise the primary function antibiotics are used
for. The biological background for this inter-kingdom signaling is also discussed.
Keywords: tetracyclines, macrolides, β-lactam, inflammation, respiratory, cardiovascular, neuroprotection, cancer
INTRODUCTION
We are all familiar with the use of antibiotics for treatment of
infectious diseases. But antibiotics do not only kill bacteria, their
original role possibly involved signaling functions (Davies et al.,
2006; Linares et al., 2006; Yim et al., 2006, 2007; Martínez, 2008;
Aminov, 2009; Romero et al., 2011). These functions, usually per-
formed at lower concentrations, are different from those leading to
cell death, and they are realized through different sets of molecular
targets in the cell. While many aspects of this communication in
the microbial world remain elusive, there is a large body of infor-
mation regarding the signaling effects of low-dose antibiotics on
humans and animals beyond the intended antimicrobial activities.
Thus the intention of this article is to undertake an interdisci-
plinary coverage of and familiarize biologists with this aspect of
non-antimicrobial antibiotic use in clinical research and practice.
The results covered in this review have been collected in various
animal models, tissue cultures, and pre-clinical and clinical tri-
als, with little or no involvement of microbiology, and, therefore,
might have escaped the attention of microbiologists. I believe this
interdisciplinary coverage is highly important to close the gap in
non-antimicrobial use of antimicrobials for a number of reasons.
First of all, it is the speciﬁcs of this type of therapy, with the use
of low-dose antibiotics for very extended periods of time mea-
sured in weeks, months, and even years. Second, while in clinical
microbiology a great deal of attention is paid to the appearance of
antibiotic resistance as a side effect of antibiotic therapy, this aspect
has had a relatively low priority and has been largely overlooked in
the low-dose long-term antibiotic treatment trials. Another aspect
that may need more careful consideration in this type of therapy
is the role of commensal microbiota, which is also an important
player in human metabolism and physiology. Antibiotics act not
only on the targets in the human body but also on the microbiota,
which is the integral part of human metabolism and physiology.
And as we know, the role of commensal microbiota in human
health and disease is immense, affecting almost every aspect of it.
Thus the antibiotic effects have to be evaluated from both sides
of their activities, including the direct interaction of antibiotics
with the host cells as well as indirect, through the modulation of
microbiota and, correspondingly, microbial metabolites, macro-
molecules, andother biologically active components of microbiota
that affect the host. And ﬁnally, it is intriguing to recognize how
many molecular targets for antibiotics are in the human body. Is it
by chance that they have such pleiotropic properties that are affect-
ing almost every organ or system in the human body? Only three
classes of antibiotics are covered in this review because of space
restraints. These are the macrolides, tetracyclines, and β-lactams.
For the same reason, only few most important examples for each
antibiotic class and for each group of diseases are given. These are
followed by a discussion of various implications of the effects and
consequences of the non-antimicrobial antibiotic use.
MACROLIDES
There are many examples of antibiotic signaling effects on the
host beyond the intended antimicrobial activity. The use of
macrolides for treatment of non-infectious diseases has the ear-
liest history among other antibiotics. A considerable amount of
information regarding the therapeutic potential of macrolides for
non-antimicrobial use has been collected beginning from the late
1980s. Since then, a great number of animal experiments have
been performed, many representatives of this class of antibiotics
have gone through clinical trials, and a number of drugs in this
group have been approved and are currently commonly used in
clinical practice for non-antimicrobial purposes.
The use of macrolides has been especially successful in theman-
agement of various chronic respiratory diseases not only in the role
of antimicrobial agents but also due to their anti-inﬂammatory
and pro-kinetic properties. The positive effect of long-term low-
dose administration of erythromycin to patients with diffuse pan-
bronchiolitis was demonstrated by Japanese researchersmore than
two decades ago, thus suggesting other than antimicrobial nature
of erythromycin action (Kudoh et al., 1987; Nagai et al., 1991).
From this point, the use of macrolides for non-antimicrobial
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purposes has become one of the mainstream choices for treatment
of chronic respiratory diseases.
In cystic ﬁbrosis (CF), the main bacterium associated with
the pulmonary disease is Pseudomonas aeruginosa, which pro-
duces bioﬁlms resistant to antibiotic treatment within the airways
(Singh et al., 2000). Although P. aeruginosa is naturally resistant
to macrolides, these antibiotics, even at subinhibitory concentra-
tions, can suppress quorum sensing necessary for bioﬁlm forma-
tion (Tateda et al., 2007). This mechanism possibly contributes
to the heightened sensitivity of non-susceptible P. aeruginosa
toward a variety of anti-pseudomonal agents in bioﬁlms when
exposed to macrolides at subinhibitory concentrations (Lutz et al.,
2012). In addition, low-dose macrolides display immunomod-
ulatory properties inﬂuencing cytokine production and altering
polymorphonuclear cell functions (Schultz, 2004). This prevents
excessive uncontrolled inﬂammation and associated tissue dam-
age. Another beneﬁt of the macrolide use in the management of
CF is the reduced chronic airway hypersecretion (Tamaoki et al.,
1995).
Treatment of other respiratory diseases such as asthma may
beneﬁt from the dual action of macrolides because asthma is a
result of interaction of genetic and environmental factors. The
presence of Mycoplasma pneumoniae and Chlamydophila pneu-
moniae in asthmatics best identiﬁes the macrolide responsive
phenotype because of the antimicrobial and anti-inﬂammatory
properties of macrolides covering the infection and genetic
predisposition continuum (Good et al., 2012).
Chronic obstructive pulmonary disease (COPD) remains one
of the important causes of morbidity, mortality, and health-care
costs worldwide (Mannino and Buist, 2007). Although smoking
is the most important risk factor for the disease, it also has a
substantial genetic component (Wain et al., 2012). Pathogenesis in
COPD is largely driven by dysregulated responses of the innate and
adaptive immune systems to the environmental cues leading to an
exaggerated inﬂammatory response, which results in permanent
inﬂammation, tissue damage, and lung function decline (Hol-
loway and Donnelly, 2013). A well-designed, randomized, 1-year
trial of erythromycin, at a dose of 250 mg twice daily, has found
a signiﬁcant reduction in COPD exacerbations compared to the
placebo group (Seemungal et al., 2008). Long-termadministration
of azithromycin by outpatients with severe COPD has appeared to
be safe and effective, with reduced exacerbations, hospitalizations,
and improved quality of life (Blasi et al., 2010). Another trial with
a daily azithromycin for 1 year for prevention of exacerbations
of COPD has demonstrated decreased frequency of exacerbations
and improved quality of life but has caused hearing decrements
in a small percentage of subjects (Albert et al., 2011). A recent
review of controlled clinical studies focusing on the prevention of
COPD exacerbations with long-term azithromycin, erythromycin,
or clarithromycin treatment suggests that it is effective, safe, and
cost-efﬁcient (Simoens et al., 2013). Other chronic respiratory dis-
eases may also be treated by macrolides, but better designed trials
are necessary to conﬁrm their efﬁcacy (Suresh Babu et al., 2013).
Novel effects of macrolides on cardiovascular diseases have
been discovered recently. In animal models, clarithromycin has
suppressed the development of myocarditis, cardiac rejection, and
myocardial ischemia (Nakajima et al., 2010; Suzuki et al., 2012).
The positive effect of clarithromycin in cardiovascular diseases
may be due to the alteration of inﬂammatory factors and matrix
metalloproteinases (MMPs). MMPs as a part of the extracellular
matrix participate in a number of normal physiological processes,
which contribute to tissue structure, function, and remodeling,
including the myocardium (Spinale et al., 2013). Both the expres-
sion and activity of MMPs are regulated by the tissue inhibitors
of matrix metalloproteinases (TIMPs), and the MMPs/TIMPs
balance is crucial for the normal maintenance of myocardial inter-
stitial homeostasis. Misbalance and the resulting involvement of
MMPs in disease, however, have been shown for a number of
pathologies spanning from cancer to cardiovascular diseases and
to neurodegeneration (Sbardella et al., 2012). The protective effect
of clarithromycin in the case of autoimmune myocarditis appears
to be implemented through the inhibition of the MMP-9 activity
(Hishikari et al., 2010). In the long run, however, a short-term clar-
ithromycin administration in patients with coronary heart disease
for clearance of suspected infections results in increased risk of
mortality (Gluud et al., 2008).
Immunosuppressive activities of macrolides have been known
for almost four decades now. The ﬁrst macrolide with this activ-
ity, rapamycin (also called sirolimus), was discovered by Brazilian
researchers during a screening program for antifungal compounds
produced by soil bacteria (Vézina et al., 1975). But its use as an
antifungal antibiotic has been abandoned due to potent immuno-
suppressive and antiproliferative activities. Its antiproliferative
action is realized through the formation of an active complex with
its cytosolic receptor protein, FKBP12, and targeting of a puta-
tive lipid kinase termed target of rapamycin (TOR; Brown et al.,
1994; Sabers et al., 1995; Wiederrecht et al., 1995). The loss of
TOR function leads to the inhibition of G1- to S-phase progres-
sion in various sensitive cells. The immunosuppressive activity
of rapamycin is also realized via the same protein kinase inhibi-
tion pathway affecting cell-cycle proliferation of lymphoid cells
(Abraham, 1998).
The TOR complexes regulate cell growth and metabolism in
response to environmental and intracellular cues and are com-
prised of two distinct multiprotein complexes: TOR complex 1
(TORC1), which is sensitive to rapamycin, and TORC2, which
is not (Wullschleger et al., 2006). Dysregulation of these com-
plexes is associated with various pathologies, including cancer,
cardiovascular diseases, autoimmunity, metabolic disorders, and
neurodegenerative diseases. Thus rapamycin and its derivatives
can be used for treatment of a variety of diseases (Cruzado, 2008).
It is also potentially useful for treatment of substance abuse con-
ditions, alcohol abuse in particular, since inhibition of TORC1
by rapamycin disrupts alcohol-associated memory reconsolida-
tion, leading to a long-lasting suppression of relapse (Barak et al.,
2013). Currently it is approved for prevention of transplant rejec-
tion, and its latest derivative, everolimus, is widely used to prevent
the rejectionof heart, lung, kidney, or liver allografts (Gurk-Turner
et al., 2012). Since TOR complexes are evolutionary conserved
and involved in very fundamental biological processes in the
cell, pharmacological inhibition of TOR signaling by rapamycin
increases the lifespan of yeasts and higher eukaryotes (Powers
et al., 2006). The use of rapamycin in humans as an anti-aging
agent is uncertain because of side effects; this use will require the
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development of safer derivatives, termed rapalogs (Lamming et al.,
2013).
Another macrolide compound with a potent immunosuppres-
sive activity was discovered in 1984 during the screening pro-
gram of Fujisawa Pharmaceutical Company aimed at compounds
that reduce the risk of transplant rejection (Kino et al., 1987).
This 23-membered macrolide lactone, isolated from Streptomyces
tsukubaensis and called FK-506 (later also called tacrolimus or
fujimycin), was initially approved in 1994 for the prophylaxis of
liver transplant rejection, and since then the range of its use has
expanded dramatically. In fact, it is considered as a cornerstone
of modern immunosuppressive therapy and is used to treat allo-
graft rejections that are resistant to other immunosuppressants
(Rath, 2013). The effect of this class of macrolide immunosup-
pressants is also based on targeting the evolutionary conserved
signal transduction pathways but via a mechanism other than that
of rapamycin. In particular, FK506/FKBP complex inhibits the
cytosolic phosphatase calcineurin, a key enzyme regulating the
translocation of cytosolic components of various nuclear factors
into the nucleus. Thus the blocked translocation of the cytosolic
component of the nuclear factor of activated T cells (NF-AT) leads
to its inability to activate a number of genes necessary for the pro-
liferation of T cell such as IL-2 as well as for B cell help such as
IL-4 (Ho et al., 1996).
Besides the extensive use in prophylaxis of transplant rejection,
tacrolimus has demonstrated its efﬁcacy and safety for a number
of other inﬂammatory conditions. It has been successfully used
in patients with inﬂammatory bowel disease, in particular for the
treatment of severe cases (Baumgart et al., 2006) and for the induc-
tion of remission in refractory disease (Baumgart et al., 2008). In
dermatology, the success of this drug is due to its topical effective-
nesswhile cyclosporine, a drugwith a similarmechanismof action,
is topically non-responsive (Mrowietz, 1992). In general, many
macrolide immunosuppressants, due to their chemical structure,
are highly efﬁcient in the topical form and are used extensively to
treat many dermatological disorders (Mrowietz, 1999). They lack
the skin-thinning side effect of corticosteroids and, therefore, can
be used for extended periods of time and in areas with thin skin.
Macrolides are among the safest antibiotics in clinical use, with
very few severe side effects (Periti et al., 1993). The most fre-
quent manifestation is gastrointestinal disturbance occurring in
15–20% of patients on erythromycins and in 5% or fewer patients
treatedwithnovelmacrolides. Transient deafness and allergic reac-
tions are highly unusual and usually associated with the older
macrolides. Clarithromycin and erythromycin may potentiate
calcium-channel blockers by inhibiting cytochrome P450 isoen-
zyme 3A4 (Wright et al., 2011). Therefore, the concomitant use
of calcium-channel blockers and these antibiotics may result in
signiﬁcant hypotension and shock (Wright et al., 2011; Henne-
man and Thornby, 2012). Although the risk is small, it can greater
among the elderly and patients with multiple comorbidities.
In a subset of patients the use of tacrolimus for themanagement
of hematopoietic allogeneic stem cell or solid organ transplanta-
tion is associated with a rare complication, posterior reversible
encephalopathy syndrome (PRES; Wong et al., 2003; Bartynski
et al., 2008; Hodnett et al., 2009; Wu et al., 2010; Hammerstrom
et al., 2013). The main manifestations of PRES include altered
mental status, seizures, visual abnormalities, and high blood
pressure. While it is not clear how to manage the central ner-
vous system (CNS)-related side effects, PRES associated with high
blood pressure should include adequate blood pressure control
(Hammerstrom et al., 2013).
Substantial progress has been made in identiﬁcation of mam-
malian cell targets of macrolides. As discussed above, there is an
extensive variety of targets for macrolides in the human body, and
the list continues to grow. For instance, the immunomodulatory
activities of macrolides can be mediated via the inhibition of pro-
duction of many proinﬂammatory cytokines, the formation of
leukotriene B4 (a neutrophils attractant), the formation of adhe-
sion molecules necessary for neutrophil migration, and the release
of superoxide anion by neutrophils (Tamaoki et al., 2004). The
ketolide antibiotic telithromycin exerts powerful immunomodu-
latory and anti-inﬂammatory effects through NF-κB inhibition
and enhancement of inﬂammatory cell apoptosis (Leiva et al.,
2008a,b).
The macrolide antibiotic-binding human p8 protein has been
cloned and identiﬁed using the phage display library approach
(Morimura et al., 2008). This is a nuclear DNA-binding protein,
which is strongly activated in response to several stresses, and, on
the basis of functional similarity to HMG-I/Y-like proteins, it has
been suggested that p8may be involved in transcription regulation
(Encinar et al., 2001; Hoffmeister et al., 2002). It plays an impor-
tant role in such a basic biological process as ontogeny and hence is
involved in a variety of developmental processes, such as pancreatic
development in rats (Mallo et al., 1997), temporal expressionof the
beta subunit of luteinizing hormone (LHB) during gonadotroph
development in mice (Million Passe et al., 2008), and mediation
of gene expression in the diapause-destined crustacean Artemia
franciscana (Qiu and MacRae, 2007).
In pathologies, the p8 protein is crucial for tumor development
(Vasseur et al., 2002), and it is also involved in stress responses
imposed by inﬂammation, tissue damage, and remodeling. Thus
the list of pathologies includes diseases with an inﬂammatory
component, acute pancreatitis for instance (Mallo et al., 1997). In
cardiac pathology, p8 is broadly involved in cellular events leading
to cardiomyocyte hypertrophy and cardiac ﬁbroblast MMPs pro-
duction, both of which take place in heart failure (Goruppi et al.,
2007). Since clarithromycin, erythromycin, and azithromycin
inhibit the binding of recombinant p8 protein to double-stranded
DNA (Morimura et al., 2008), the anti-inﬂammatory effect of
macrolides discussed above may be explained, at least in part,
by the down-regulation of transcription of genes involved in the
proinﬂammatorynetwork. Interestingly, the same inhibitory effect
has been observed with a structurally unrelated antifungal antibi-
otic dechlorogriseofulvin (Morimura et al., 2008), suggesting a
potential overlap in recognition of structurally different antibiotic
ligands by a single human molecular target.
The important difference between the antibiotic therapy of
“classical” infectious diseases and chronic conditions such as cys-
tic CF is the duration of antibiotic treatment. With the exception
of Mycobacterium tuberculosis and few other difﬁcult-to-eradicate
infections, the antibiotic treatment period for infectious diseases
is relatively short, while the maintenance therapy for chronic
conditions is a long-term and perhaps life-long endeavor. One
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of the consequences of the maintenance therapy might be the
selection for, and maintenance of, antibiotic resistance genes.
In recent clinical trials evaluating the efﬁciency of the long-
term azithromycin and erythromycin maintenance treatments
in patients with non-CF bronchiectasis, the level of macrolide
resistance signiﬁcantly increased, despite the subinhibitory con-
centrations used (Altenburg et al., 2013; Serisier et al., 2013).
Due to the importance of other than antibacterial activities of
macrolides as well as to reduce the possibility of antibiotic selec-
tion for resistance, efforts have been made to design macrolide
molecules with better anti-inﬂammatory activities (Kobayashi
et al., 2013). Another approach to lessen the resistance burden
is the design of macrolides that have their antimicrobial activ-
ities completely abolished but have other activities retained. It
appears that the antimicrobial and anti-inﬂammatory activities of
macrolides are independent and can be separated, thus opening
the possibility of designing macrolide-based anti-inﬂammatory
drugs lacking antimicrobial activities (Bosnar et al., 2012).
Thus the recent macrolide development efforts have bifurcated
into two directions that are focused on designing and modiﬁ-
cation of macrolides better suited either for the antimicrobial
or non-antimicrobial use. Historically, antibiotics (macrolides
included), as their name implies, have been selected primarily
for their antimicrobial activities, while other activities such as
anti-inﬂammatory went unnoticed for a long time. In a recent
non-antimicrobial antibiotic development, a novel macrolide,
solithromycin, has displayed the capability to inhibit NF-κB and
demonstrated better anti-inﬂammatory activities in vitro com-
pared to more conventional macrolides used in the clinic such as
erythromycin, clarithromycin, azithromycin, and telithromycin
(Kobayashi et al., 2013). A better anti-inﬂammatory proﬁle of
this macrolide makes it a good candidate for the manage-
ment of chronic respiratory diseases. Another macrolide with
a signiﬁcantly diminished antibiotic activity, 2′-desoxy-9-(S)-
erythromycylamine, prevents neutrophil elastase-induced mucus
stasis and dehydration and, therefore, may be used for the
management of CF and COPD theoretically without affect-
ing antibiotic resistance proﬁle (Tarran et al., 2013). Synthetic
mimetics of actin-binding macrolides may provide a range of
designer compounds to treat actin-associated diseases (Perrins
et al., 2008). On the other hand, there are continuous efforts
to modify the existing macrolides to contain pathogens that
are becoming resistant to older macrolides. Recent develop-
ments, for example, have been based on the use of azalide
scaffold (Ištuk et al., 2011; Sugimoto et al., 2012), which was
originally implemented in 9-dihydro-9-deoxo-9a-methyl-9a-aza-
9a-homoerythromycin A (azithromycin), the antibiotic with
outstanding pharmacokinetic properties (Amsden, 2001; Mutak,
2007).
TETRACYCLINES
Tetracycline family of antibiotics is one of the best-studied exam-
ples of non-antimicrobial effects of antibiotics on the host.
Tetracyclines possess multiple and potent biological activities, and
minocycline, the best exemplary compound of this class, displays
anti-inﬂammatory, neuroprotective, anti-proteolytic, and anti-
apoptotic properties as well as inhibits angiogenesis andmetastatic
growth (Garrido-Mesa et al., 2013). In addition, it displays antiox-
idant activity, inhibits several enzyme activities, and regulates
immune cell activation and proliferation.
Similar to the macrolides discussed above, tetracyclines are
able to inhibit MMPs; this discovery was actually made in 1983,
i.e., before the discovery of the corresponding activity among
macrolides (Golub et al., 1983). As mentioned before, MMPs
are involved in a number of pathologies, including metastatic
growth, cardiovascular diseases, neurodegeneration, and a variety
of inﬂammatory conditions (Sbardella et al., 2012). Thus the inhi-
bition of MMPs may be a valuable option in treatment of a broad
spectrum of diseases. Interestingly, the inhibitory effect on MMPs
is realized through several targets/mechanisms ranging from indi-
rect effects of regulatorynetwork todown-regulationof expression
and to direct interference with enzymatic activity. These activi-
ties can include binding divalent cations such as Ca2+ and Zn2+,
inhibition of neutrophil migration and degranulation, and sup-
pression of synthesis of oxygen radicals (Gabler and Creamer,
1991). Administration of minocycline to diabetic rats, for exam-
ple, normalized the activity of four MMPs, while in in vitro assays
minocycline inhibited only collagenase and gelatinase activities,
with no inhibition of elastase and β-glucuronidase (Chang et al.,
1996). The inhibitory effect of tetracycline on stromelysin is medi-
ated via transcriptional inhibition involving sequences upstream
of the activating protein complex 1 binding site (Jonat et al., 1996).
But doxycycline, for example, down-regulates MMP-8 induc-
tion at both the mRNA and protein levels (Hanemaaijer et al.,
1997). It also disrupts the conformation of the hemopexin-like
domain of MMP-13 and the catalytic domain of MMP-8 (Smith
et al., 1999).
Presently the only MMPs-targeting tetracycline that has been
approved by the US Food and Drug Administration (FDA) and
other national regulatory agencies in Canada and Europe is the
low-dose formulation of doxycycline for the adjunctive treatment
of chronic periodontal disease (Gu et al., 2012). Other condi-
tions for potential application of low-dose tetracyclines to inhibit
the pathological effects of MMPs are: (i) cardiovascular diseases
such as coronary artery disease (Payne et al., 2011), hypertension
(Castro et al., 2011), atherosclerosis (Gu et al., 2011), and abdom-
inal aortic aneurysm (Abdul-Hussien et al., 2009); (ii) pulmonary
diseases such as acute respiratory distress syndrome (ARDS) for
which there is no approved medication (Roy et al., 2011), and
COPD (Dalvi et al., 2011); (iii)metastatic cancers (Lokeshwar,
2011; Richards et al., 2011); and (iv) systemic bone loss conditions
(Payne and Golub, 2011).
In many studies tetracyclines have demonstrated excellent
anti-inﬂammatory activities achieved through the inhibition of
chemotaxis, granuloma formation, nitric oxide production, and
protease activities (Weinberg, 2005;Webster and Del Rosso, 2007).
Positive effects of minocycline have been observed in animal mod-
els of rheumatoid arthritis (RA; Sewell et al., 1996), and this effect
has been conﬁrmed in several clinical trials as well (Greenwald,
2011). Tetracycline treatment of RA, however, is not widespread
because of the almost universal use of methotrexate. Based on
the results of successful clinical trials, subinhibitory concentra-
tions of doxycycline and minocycline were approved by the FDA
for the treatment of skin conditions and infections that have a
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substantial inﬂammatory component (Del Rosso, 2007). Another
FDA approval, after successful clinical trials, has been obtained
for the long-term management of chronic periodontitis by suban-
timicrobial doses of doxycycline (SDD) (Caton and Ryan, 2011).
This host modulatory therapy is directed against excessive MMPs
activities that are implicated in degradation of connective tissue
collagen surrounding and supporting the teeth. This effect may
have broader implications for other bone loss conditions (Payne
and Golub, 2011).
Following the ﬁrst reports on the neuroprotective effects of
minocycline in animal models of cerebral ischemic injury (Yrjan-
heikki et al., 1998, 1999), doxycycline was proposed as a candidate
for clinical trials of acute neurologic injury (Elewa et al., 2006).
Among other tetracyclines, the neuroprotective potential of the
second-generation antibiotic, minocycline, is remarkable. Its
effect has been conﬁrmed in experimental models of ischaemia,
traumatic brain injury and neuropathic pain, and of several neu-
rodegenerative conditions including Parkinson’s disease (Wu et al.,
2002), Huntington’s disease (Chen et al., 2000; Wang et al., 2003),
Alzheimer’s disease (Choi et al., 2007), amyotrophic lateral scle-
rosis (ALS; Tikka et al., 2002; Zhu et al., 2002), multiple sclerosis
(MS; Metz et al., 2004; Zabad et al., 2007), and spinal cord injury
(Marchand et al., 2009).
Presently, the results of several clinical trials aimed at the esti-
mation of neuroprotective effects of minocycline are available,
although with rather discouraging outcomes compared to ani-
mal studies. A phase III randomized trial of minocycline in ALS
patients actually demonstrated a harmful effect of minocycline
(Gordon et al., 2007). A futility study of minocycline in Hunt-
ington’s disease precluded proceeding with a phase III clinical
trial (Schwarz et al., 2010). A prospective study with a cohort of
multiple-system-atrophy Parkinson-type patients failed to show
a clinical effect of minocycline on severity of symptoms (Dodel
et al., 2010). Although the results of a phase II placebo-controlled
randomized trial of minocycline in acute spinal cord injury did
not establish efﬁcacy, several outcome measures had a tendency
toward improvement (Casha et al., 2012).
Treatment of a psychiatric illness relies on a combination of
psychological and biological approaches. The latter have been for
a long time focused on pharmacological interventions targeting
mainly the neurotransmitter systems, but there is a growing body
of evidence that these conditions are system-wide and include
oxidative stress, inﬂammation, changes in glutamatergic path-
ways and neurotrophins as well (Dean et al., 2012). Minocycline is
known as a modulator of glutamate-induced excitotoxicity and,
in addition, it possesses antioxidative, anti-inﬂammatory, and
neuroprotective properties. Pleiotropic properties of minocycline
targetingmultiple proteins and cellular processes implicated in the
pathoetiology of mood disorders make it a suitable candidate for
treatment of depression (Soczynska et al., 2012). It may be a valu-
able adjunctive therapeutic agent to antipsychotic medication in
patients with schizophrenia as well (Miyaoka, 2008). In a clinical
ad-on trial, minocycline treatment of early-phase schizophrenia
patients improved negative symptoms and cognitive functions
(Levkovitz et al., 2010). A recent preliminary open-label study
has suggested that minocycline, in combination with antidepres-
sants, is effective and well-tolerated in the treatment of unipolar
psychotic depression (Miyaoka et al., 2012). In a mouse model of
Fragile X syndrome (FXS), an inherited disorder with intellectual
disability and behavior at the extreme of the autistic spectrum,
minocycline showed potential to treat mental retardation and
associated behavior (Bilousova et al., 2009; Rotschafer et al., 2012).
Recent FXS clinical trials have indicated that minocycline may be
effective in treating human patients as well (Siller and Broadie,
2012). In a number of cognitive impairment models minocycline
treatment demonstrated promising results (Jin et al., 2013; Kong
et al., 2013; Li et al., 2013). In a recent clinical trial evaluating the
effect of minocycline on HIV-associated cognitive impairment,
however, no signiﬁcant improvement in cognitive functions has
been found (Nakasujja et al., 2013).
Microglia are glial cells, the only resident immune cells in the
CNS that respond to infections and brain injury and are actively
involved in brain development and function as well as in neurode-
generative disease (Miyamoto et al., 2013). In the normal brain,
these cells contribute to neuronal proliferation and differentiation,
pruning of dying neurons, synaptic remodeling, and clearance
of debris and aberrant proteins (Harry, 2013). Analogous to the
activities of immune cells, activated microglia release cytokines,
chemokines, nitric oxide, and reactive oxygen species (Harry,
2013). Dysfunctions in the homeostatic role of microglia, how-
ever, can affect neuronal functions such as cognition, personality,
and information processing (Miyamoto et al., 2013).
Minocycline is known as the only drug capable of inhibit-
ing the activation and proliferation of microglia (Tikka et al.,
2001). In pathologies such as global brain ischemia, suppres-
sion of microglial activation by tetracyclines has a neuroprotective
effect with a much better survival rate of CA1 pyramidal neu-
rons (Yrjanheikki et al., 1998). The neuroprotective effects of
tetracyclines in brain hypoxia are mainly due to the selective
down-regulation of proinﬂammatory cytokines and compounds
in the microglia (Lai and Todd, 2006). Overly rapid correction
of chronic hyponatremia can lead to a severe demyelination dis-
ease, and the inhibition of microglial activation by minocycline
prevents neurologic impairment and improves the survival rate
(Suzuki et al., 2010). Minocycline also protects against microglial
activation, neuronal death, and cognitive impairment caused by
severe hypoglycemia in diabetic patients (Won et al., 2012). In the
normal brain, the corresponding activity of minocycline modu-
lates human social behavior leading to a more situation-oriented
decision-making, possibly by suppressing the effects of personal-
ity traits (Kato et al., 2012). Minocycline also signiﬁcantly reduces
the risky trusting behavior in human economic exchange (Watabe
et al., 2013).
This, not exhaustive but still impressive, list of conditions
and diseases that can be treated with tetracyclines suggests the
pleiotropic effects and the presence of multiple targets and
receptors for which tetracyclines are ligands. In addition to
the discussed above, the known anti-inﬂammatory activities of
minocycline are achieved through the inhibition of expression of
nitric oxide synthases (Amin et al., 1996), suppression of B and T
cell function (Sewell et al., 1996), reduction of cyclooxygenase-2
expression and prostaglandin E(2) production (Yrjanheikki et al.,
1999), and up-regulation of IL-10 (Ledeboer et al., 2005). Anti-
apoptotic effects are believed to be due to inhibition of activity
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of caspase-1 and caspase-3 (Chen et al., 2000), inhibition of the
phosphorylationof p38mitogen-activatedprotein kinase (MAPK)
(Du et al., 2001; Joks and Durkin, 2011), and inhibition of mito-
chondrial permeability-transition-mediated cytochrome c release
(Zhu et al., 2002). By virtue of itsmolecular structure,minocycline
is also an effective antioxidant with a radical scavenging potency
similar to vitamin E thus providing excellent protection against
oxidative stress (Kraus et al., 2005).
Tetracyclines are generally well-tolerated but under particu-
lar environmental conditions and in a subset of certain age and
disease cohorts may provoke adverse reactions. One of the most
known and well-studied side effects of tetracycline administration
are cutaneous adverse events due to the increased photosensitivity
of the skin, typically to the UVA spectrum of light (Drucker and
Rosen, 2011; Glatz and Hofbauer, 2012). Clinically these effects
can be divided into two groups, phototoxic and photoallergic
reactions. The former is due to the formation of reactive oxygen
species, with the impairment of many cellular macromolecules,
thus leading to inﬂammation and apoptosis, while the latter is
a type IV hypersensitivity reaction resembling eczema. The pre-
ventive measures include avoiding direct sunlight and the use of
sunscreens. The culprit drug can be withdrawn if the reactions
persist (Glatz and Hofbauer, 2012).
Tetracyclines are generally not recommended for pediatric
patients because these compounds chelate calcium ions, which are
incorporated into teeth, resulting in discoloration of both the pri-
mary and permanent dentitions (Sánchez et al., 2004). There are
many case reports on the association of tooth, bone, nail, and scle-
ral pigmentation following minocycline administration in adults
as well but no systematic studies have been done in this area.
Many inﬂammatory diseases such as Alzheimer’s, Parkinson’s,
Huntington’s, familial Mediterranean fever, and others tend to
display a substantial protein deposition bias, where a normally
soluble protein is deposited in an insoluble amyloid form (Carrell
and Lomas, 1997). The deposits interfere with cellular functions,
eventually leading to the cell death (Thomas et al., 1995). Tetracy-
clines are known to inhibit the deposition process (Sirangelo and
Irace, 2010) but at the cost, by keeping the amyloid protein in a
pre-ﬁbrillar, highly cytotoxic state (Malmo et al., 2006). So care
should be exercised to avoid the toxic effects of oligomeric species
during tetracycline therapy.
In adevelopment analogous to the search for non-antimicrobial
macrolides there have been a series of works aimed at designing
tetracycline derivatives with diminished antimicrobial activities
while retaining or enhancing other activities important for their
non-antimicrobial use. It needs to be noted here that the works
with non-antimicrobial tetracycline derivatives have been actually
initiated earlier than those with macrolides, i.e., shortly after the
discovery of the host modulating properties of low-dose tetracy-
clines 30 years ago (Golub et al., 1983). However, a closer look
into literature shows that the host modulating effects of antibiotic
derivatives were detected even earlier, in 1950 (Stokstad and Jukes,
1950). In one of their experiments, the discoverers of growth-
promoting antibiotics found that the cultural supernatant of S.
aureofaciens, in which the antibiotic activity of aureomycin is
destroyed by alkaline hydrolysis, still enhanced the growth and
improved survival of chicks when added to feed (Stokstad and
Jukes, 1950). Thus, the loss of antimicrobial activity of aureomycin
has not compromised its other biological activities such as growth
promotion. It is unfortunate that this interesting observation has
been left without attention it deserves for so many years.
Chemically modiﬁed tetracyclines with no antimicrobial activ-
ity may have numerous applications without the associated
risk of selecting for antibiotic resistance. For example, chemi-
cal conversion of tetracycline hydrochloride to the analog with
no antimicrobial activity, de-dimethylaminotetracycline, has not
compromised the collagenase inhibitory activity of the original
molecule (Golub et al., 1987), while not affecting the tetracy-
cline resistance proﬁles of gut and oral microbiota (Golub et al.,
1991). COL-3, a chemically modiﬁed tetracycline with a MMP
inhibitor activity, has showed promising results in the treatment
of AIDS-related Kaposi’s sarcoma (Dezube et al., 2006). More-
over, the use of modiﬁed tetracyclines has showed promising
results inmanyﬁelds, includingophthalmologic diseases (Federici,
2011), dentistry (Grenier et al., 2002; Gu et al., 2012), cardio-
vascular pathologies (Salo et al., 2006; Gu et al., 2011), various
types of cancer (Lokeshwar, 1999, 2011; Syed et al., 2004; Zhao
et al., 2013a), and other conditions with excessive MMPs activities
(Golub, 2011).
Another direction in the development of tetracyclines is under-
standably focused on the design of drugs with better antimicrobial
activities and pharmacokinetic properties. Despite being highly
efﬁcient upon introduction in the clinical practice in the 1950s, the
widespread resistance to the ﬁrst- and second-generation tetra-
cyclines made them essentially useless for treatment of many
serious infectious diseases. One of the successful drug discov-
ery programs resulted in a third-generation tetracycline called
tigecycline (the minocycline derivative 9-tert-butyl-glycylamido-
minocycline). The antibiotic is highly efﬁcient against a broad
range of pathogenic bacteria, including those resistant to the
ﬁrst- and second-generation tetracyclines (Bertrand and Dowz-
icky, 2012). Although it is on the list of reserve drugs, its use is
steadily increasing (Huttner et al., 2012). Regrettably, similar to
the fate of other antibiotics, the efﬁciency of tigecycline may start
to deteriorate due to the penetration of tigecycline resistance into
pathogenic microbiota (Aminov, 2013).
β-LACTAMS
One of the most remarkable breakthroughs in the search for the
therapy of neurodegenerative diseases has identiﬁed β-lactams
as a very promising group of drugs. In a large screening effort
involving 1,040 FDA-approved drugs and nutritionals, it has been
discovered that the only drugs capable of regulating the expression
and modulating the activity of the glutamate transporter subtype
1 (GLT-1) are β-lactams (Rothstein et al., 2005). Glutamate is a
principal excitatory neurotransmitter in the CNS and contributes
to learning and memory (Shigeri et al., 2004). The concentration
of glutamate is mainly handled by GLT-1 (excitatory amino-acid
transporter 2, EAAT2, responsible for 90% of glutamate uptake;
Danbolt, 2001). Impairment of EAAT2 function leads to excess
of glutamate and associated glutamate excitotoxicity destroying
neurons and leading to neurodegenerative diseases such as ALS,
epilepsy, and others (Maragakis and Rothstein, 2001). No prac-
tical pharmaceuticals modulating EAAT2 expression and activity
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were known until the discovery of such activity among β-lactams
(Rothstein et al., 2005). A multi-phase randomized trial of ceftri-
axone for treatment of ALS has been recently ﬁnalized (Berry et al.,
2013).
Similar to other antibiotics, β-lactams can target many com-
ponents of the eukaryotic cellular machinery, and the effects of
β-lactams are not limited solely to the modulation of expression
and activity of EAAT2. In a recent investigation of ceftriaxone as a
potential therapy using a murine model of spinal muscular atro-
phy, the effects, in addition to the increase of EAAT2, also included
the increase of the nuclear factor (erythroid-derived 2)-like 2,
Nrf2, and the spinal muscular atrophy protein SMN (Nizzardo
et al., 2011). The treatment resulted in signiﬁcant amelioration of
the neuromuscular phenotype and increased survival consistent
with the protection of neuromuscular units through the activa-
tion of antioxidant response pathway governed by Nrf2. Another
work has pointed to this target of ceftriaxone as well: together
with the induction of the cystine/glutamate transporter SLC7A11
(formerly xCT), the neuroprotective effect of ceftriaxone in vitro
is combined with the induction of Nrf2 consistent with the activa-
tion of the antioxidant defense system of the cell (Lewerenz et al.,
2009).
In various models of brain injury ceftriaxone demonstrates
strong neuroprotective effects, mainly via the up-regulation of
GLT-1. In an experimental model of focal cerebral ischemia, the
administration of ceftriaxone induces ischemic tolerance result-
ing in a better functional recovery of animals (Chu et al., 2007).
A dramatic survival improvement can be seen in a rat model of
stroke, if the animals are treated by a single injection of ceftriaxone
90 min after the middle cerebral artery occlusion (Thöne-Reineke
et al., 2008). Pre-treatment with ceftriaxone also confers a signif-
icant neuroprotection in a cerebral ischemia/reperfusion injury
(Verma et al., 2010). In a neonatal rat model of hypoxic–ischemic
encephalopathy, pre-treatment with the antibiotic signiﬁcantly
reduces the brain injury scores and apoptotic cells in the hip-
pocampus, restores myelination in the external capsule, and
improves the posttraumatic learning and memory deﬁcits (Lai
et al., 2011). The neuroprotective effects of ceftriaxone are real-
ized not only through the regulation of expression and activity
of GLT-1, SLC7A11, and Nrf2. In a rat model of traumatic brain
injury the antibiotic also signiﬁcantly reduces the level of proin-
ﬂammatory cytokines (Wei et al., 2012). Thus the improvement
of cognitive functions and mitigation of brain edema after a
brain injury, which is treated by posttraumatic administration
of ceftriaxone, is a combined effect of reduced excitotoxicity and
suppressed inﬂammation.
The potent immunomodulatory properties of β-lactam antibi-
otics, including inﬂammation control, are not limited to the sole
example given above (Wei et al., 2012). In a mouse model of MS,
ceftriaxone treatment indirectly hampered T cell proliferation and
secretion of proinﬂammatory cytokines thus attenuating the dis-
ease course and its severity in this model of autoimmune CNS
inﬂammation (Melzer et al., 2008). Interestingly, ceftriaxone has
had no impact on the EAAT2 protein expression levels in sev-
eral brain areas as well as on the glutamate uptake rate suggesting
that in this model the positive effects of the antibiotic are not
mediated through the modulation of glutamate concentration.
Moreover, it seems that even the individual antibiotics within
the β-lactam group may display differential immunomodulatory
properties (Mor and Cohen, 2013). This mechanism operates via
covalent binding of various β-lactams to cellular albumin and
subsequent modulation of T cell function and gene expression.
β-lactams may be considered as valuable candidates for treat-
ment of alcohol and other drug dependencies due to the capability
of normalizing glutamate transmission, which is affected in addic-
tion (Kalivas et al., 2009). To start with the simplest model:
in planarians, ceftriaxone attenuates both the development of
physical dependence and abstinence-induced withdrawal from
cocaine, amphetamine, methamphetamine, and benzodiazepine
(Rawls et al., 2008). In rats, the administration of ceftriaxone may
suppress cue- and cocaine-induced relapses to cocaine-seeking
behavior via up-regulation of GLT-1 and SLC7A11 (Sari et al.,
2009; Knackstedt et al., 2010). Ceftriaxone also precludes cocaine
sensitization and provides a long-term attenuation of cue- and
cocaine-primed reinstatement of cocaine-seeking behavior, even
after the cessation of antibiotic administration (Sondheimer and
Knackstedt, 2011). In general, the antibiotic normalizes many
aspects of glutamate homeostasis disrupted by the use of cocaine
and, therefore, has the potential to lessen relapse episodes in
human cocaine addicts (Trantham-Davidson et al., 2012). Cur-
rently there is no approvedmedication for the treatment of cocaine
addiction, and the promising results obtained in the animal model
experiments described above suggest that ceftriaxone (and possi-
bly other β-lactams) can be considered as good candidates for
clinical trials.
The biggest substance abuse problem is associated with exces-
sive ethanol consumption, and β-lactams hold the potential to
contribute to this problem as well. The biochemistry of ethanol
addiction is more complicated compared to other drug depen-
dencies, but one of its components discussed above, i.e., changes
in glutamate transmission, is affected analogous to other drug
addictions (Rao and Sari, 2012). Possibly the same mechanism
of normalization, through the activation of GLT-1 by ceftriax-
one, contributes to reduced ethanol consumption as well as to
attenuation of relapse-like ethanol-drinking behavior in male
alcohol-preferring rats (Sari et al., 2011; Qrunﬂeh et al., 2013).
Reduction in the acquisition andmaintenance of ethanol-drinking
habit by ceftriaxone has also been veriﬁed for adolescent and adult
female alcohol-preferring rats (Sari et al., 2013).
Enhanced glutamatergic transmission is a primary mediator
of opiate dependence, and the counteractive effect of ceftriax-
one prevents the development of morphine physical dependence
in rats (Rawls et al., 2010a). Through the same remedial mecha-
nism, the antibiotic reduces morphine analgesic tolerance (Rawls
et al., 2010b) and suppresses opioid-induced hyperalgesia (Chen
et al., 2012). The efﬁcacy of ceftriaxone against drug dependence-
related behavior extends to amphetamine (Rasmussen et al., 2011)
and nicotine (Alajaji et al., 2013), as well as to the prevention of
cannabinoid tolerance (Gunduz et al., 2011).
In general even the higher doses of ceftriaxone are tolerated
well but care should be taken in neonates, especially those with
hyperbilirubinemia and those receiving intravenous calcium solu-
tions (Monte et al., 2008). There is no support for such restrictions
in patients >28 days old (Steadman et al., 2010). The adverse
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reactions to ceftriaxone are caused by rapid intravenous injec-
tion, unlabeled use, and past history of allergic reactions to
cephalosporins or penicillins (Shalviri et al., 2012). These risk
factors can be easily managed under the normal clinical settings.
The host modulating properties of β-lactams have been discov-
ered recently, and there is yet no data regarding the development
of β-lactams with abolished antimicrobial activity. Unlike the
macrolides and tetracyclines, the non-antimicrobial effects of
β-lactams have been studied mostly with a single representative,
ceftriaxone, and it is not clear if other representatives of this
class of drugs possess similar properties. Another problematic
area in ceftriaxone application for non-antimicrobial purposes is
the concentrations used. The concentrations may be even higher
than those for infectious disease treatment thus exerting potent
selective pressure on commensal and pathogenic microbiota. This
third-generation cephalosporin still remains a valuable therapeu-
tic option for treatment of pneumonia, bacterial meningitis, Lyme
disease, typhoid fever, and gonorrhea. Although the drug is los-
ing its position as the last remaining option for ﬁrst-line empiric
treatment of, for example, Neisseria gonorrhoeae (Unemo and
Nicholas, 2012), there are still some pathogens that have not
acquired the corresponding resistance as yet. In this situation,
exerting additional selective pressure by the non-antimicrobial use
of ceftriaxone may complicate the management of a number of
infectious diseases.
DISCUSSION
Based on many promising results of the non-antimicrobial use of
antimicrobials, the use of antibiotics for this purpose is expected
to rise dramatically. Although being considered in the most
recent clinical trials, a possible side effect of this therapy, such as
the emergence and dissemination of antibiotic resistance among
commensals and pathogens, has not received any considerable
attention, and, in fact, the majority of clinical trials cited here have
not monitored the occurrence of antibiotic resistance. There are
some indications, however, that even low, non-selective concen-
trations of antibiotics used for a long timemay affect the antibiotic
resistance proﬁle of human microbiota. For example, in a recent
clinical trial of long-term, low-dose erythromycin on pulmonary
exacerbations among patients with non-CF bronchiectasis, the
proportion of macrolide-resistant oropharyngeal streptococci at
the end of therapy has been substantially higher in the treatment
group compared to the placebo group, 27.7 vs. 0.04%, respec-
tively (Serisier et al., 2013). The use of azithromycin for the same
purpose has resulted in the macrolide resistance rate of 88% com-
pared to 26% in the placebo group (Altenburg et al., 2013). In
this regard, the use of modiﬁed antibiotics with abolished antimi-
crobial activities may be helpful to circumvent such undesirable
side effects of this type of therapy (Golub et al., 1991). Efforts to
design newer antibiotic derivatives, which have no antimicrobial
properties must be continued, especially for β-lactams that are
used at the concentration range far exceeding those employed in
infection control. For example, the recommended dose of ceftri-
axone for treatment of gonorrhea has been increased from 125 to
250 mg due to the increasing resistance of N. gonorrhoeae, where
for the majority of other infections the range rarely exceeds 1–
2 g per day. But the most efﬁcient management of, for example,
ALS may require dosages up to 4 g/day (Berry et al., 2013). In
combination with a generally long-term treatment required for
this type of therapy (i.e., 20 weeks used in Berry et al., 2013),
the total quantity of ceftriaxone consumed during a single course
(560 g)might easily exceed the corresponding values used in a typ-
ical infection treatment by approximately 30–60 times. This may
contribute to a signiﬁcantly broader spread of resistance against
third-generation cephalosporins among human commensals and,
possibly, pathogens.
This clearly powerful selective pressure of ceftriaxone to be
used for non-antimicrobial purposes brings forward another con-
sideration for a more careful assessment of the biotic effects
of antibiotics: that is, whether the effects of antibiotics are
exerted solely via the human receptor-antibiotic ligand mecha-
nisms. While the in vitro models largely have no issues with the
inﬂuence of an indirect factor such as commensal microbiota, the
corresponding experiments with animal models or human volun-
teers may need more careful interpretation because of a possible
interfering effect of this often neglected variable. Our views on the
role of commensal microbiota in human health and disease have
undergone cardinal changes during the last decade from view-
ing it as a fairly passive bystander with a limited contribution to
the host nutrition to an active organ of our body involved in many
aspects of ourmetabolism, physiology, immunity, anddisease. The
ﬁeld of host–microbiota research is overloaded with many works
revealing the role of commensal microbiota in various pathologies
ranging from inﬂammatory disorders to metabolic syndrome and
to autism. It is, however, not possible to extend the frames of this
review to include this fascinating area as well.
It is interesting to note, though, that there is an overlap between
the range of diseases that can be treated by the biotic action of
antibiotics and the diseases that have a substantial commensal
microbial component. In Parkinson’s disease subjects, for exam-
ple, the integrity of the intestinal lining is compromised thus
allowing translocation of proinﬂammatory bacteria and bacterial
products leading to the formation of the pathological hallmark of
the disease, i.e., Lewy bodieswith alpha-synuclein protein (Forsyth
et al., 2011). As discussed above, the neuroprotective effects of
minocycline may include reduced mitochondrial calcium uptake,
stabilized mitochondrial membranes, reduced release of apop-
totic factors, up-regulation of the anti-apoptotic protein Bcl-2,
direct scavenging for reactive oxygen species, and inhibition of
MAPKs (Orsucci et al., 2009). On the other side, minocycline may
affect and modulate the microbiota, both commensal and translo-
cated, thus reducing the load of proinﬂammatory bacteria and
bacterial products. The effect on microbiota may be particularly
profound for ceftriaxone, the biotic use concentration of which
is much higher than typical antimicrobial concentrations used for
infectious diseases. At concentrations used for typical antibacterial
therapy, the ceftriaxone-induced dysbacteriosis may signiﬁcantly
change the fecal metabolome and affect the populations of T lym-
phocytes, their subpopulations in Peyer’s patches, and expression
of various cytokines (Gao et al., 2012; Zhao et al., 2013b). Thus
ceftriaxone considerably modiﬁes the gut microbiome with the
subsequent alteration of the host metabolome and immunity. It is
currently unknown towhat extent these secondary alterations con-
tribute to theobserved therapeutic effects of thenon-antimicrobial
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy August 2013 | Volume 4 | Article 241 | 8
“fmicb-04-00241” — 2013/8/16 — 21:17 — page 9 — #9
Aminov Biotic acts of antibiotics
ceftriaxone use in various diseases and pathologies. Because of
the dual role of antibiotics, further research on biotic effects
of antibiotics should incorporate both of these aspects in study
designs.
Similarly, in the use of antibiotics as antimicrobial agents,
their biotic effects are rarely considered as signiﬁcant. Almost
all infectious diseases, however, have a substantial inﬂammatory
component, and, if left unchecked, the host’s proinﬂammatory
responses may cause more harm than a pathogen would. In
this regard, the anti-inﬂammatory activities of tetracyclines and
macrolides discussed abovemay help to alleviate the overly aggres-
sive inﬂammatory responses and prevent the resulting excessive
tissue damage. In general, the number of diseases with a sig-
niﬁcant proinﬂammatory component, as exempliﬁed above in
this review, is on the rise, and one of the possible explana-
tions for this phenomenon is offered by the hygiene hypothesis
(Strachan, 1989). There used to be substantial exposure of humans
to environmental bacteria before the advent of industrial food
production resulting in essentially sterile food protected by preser-
vatives, conservatives and freezing and generally higher hygienic
standards of living. This exposure seems to have been an essen-
tial component of the immune system education and the lack of
it results in an unbalanced immune system development, with a
prominent proinﬂammatory bias. Thus antibiotics like tetracy-
clines and macrolides not only help to clear infections but also
prevent generally excessive immune responses to infections char-
acteristic for modern humans. Other antibiotics, however, may
display the opposite biotic effects. For example, rifampin, a major
drug used in tuberculosis treatment, increases inducible nitric
oxide synthase expression and NF-κB activation and decreases
PPARgamma expression (Yuhas et al., 2009), thus displaying
strong proinﬂammatory properties.
The ligand and signaling activities of antibiotics that are beyond
their intended antimicrobial use may explain the phenomena out-
side the human disease domain. Many are probably familiar with
the growth-promoting effect of antibiotics on food animals. The
growth-promoting antibiotics were completely phased out in the
EU countries in 2006 because of their alleged contribution to
the spread of antibiotic resistance, but it is still a legal practice
in many countries. Despite the fact that the growth-promoting
phenomenon was discovered more than 60 years ago, its mecha-
nisms are still poorly understood. One of the possible explanations
proposed has been the suppression of subclinical infections. But
the concentrations of antibiotics used for growth promotion are
well below the minimal inhibitory concentration (MICs) for the
majority of pathogens. The irony of the situation is that it has
been clear from the beginning that the growth-promoting effects
of antibiotics are not due to antimicrobial activities. Since the
very early days of the ﬁeld it has been shown that even if the
antibiotic activity of aureomycin in the culture supernatant of
S. aureofaciens is destroyed by alkaline hydrolysis, it still retains
the complete growth-promoting potential (Stokstad and Jukes,
1950). Thus Robert Stokstad and Thomas Jukes were the ﬁrst to
witness the biotic activity of the modiﬁed antibiotic but without
realizing this. In the context of results discussed in this review,
it is probable that the growth-promoting effect of antibiotics is
largely due to the biotic signaling. This may affect the host and
microbial components and can be realized through the modula-
tion and pleiotropic regulation of the physiology and metabolic
state of an entire microbiota as well as the regulatory mechanisms
operating in the host animal. The regulatory effect of antibi-
otics on the microbial component has been discussed elsewhere
(Davies et al., 2006; Linares et al., 2006; Yim et al., 2006, 2007;
Martínez, 2008; Aminov, 2009; Romero et al., 2011). Other regu-
latory effects can be instigated through signaling to the host cells
as has been demonstrated in this review. This could bemodulation
of immunity by suppressing subclinical inﬂammatory processes,
which drain the host resources. It is probably not a coincidence
that the vast majority of growth-promoting antibiotics belong to
macrolides and tetracyclines that exert potent anti-inﬂammatory
activities.
And ﬁnally, moving from the applications to the fundamentals,
it remains to be discussed whether this multiplicity of antibiotic
targets in the human/animal body we have just seen is merely acci-
dental. Our perception of antibiotics as instruments of warfare
in microbial communities is mainly inﬂuenced by the extrapo-
lation of antibiotic use in clinical and veterinary microbiology,
where high concentrations of antibiotics are used to eradicate bac-
terial infections in humans and animals. Several lines of evidence
gathered in recent years suggest that antibiotic concentrations
occurring in natural ecosystems are too low to kill the neighbors
and, instead, theymayplay signaling and regulatory roles inmicro-
bial communities (Davies et al., 2006; Linares et al., 2006; Yim
et al., 2006, 2007; Martínez, 2008; Aminov, 2009; Romero et al.,
2011). The concept of antibiotics serving as signaling molecules in
microbial ecosystems has gained considerable attention also in the
context that it may explain the effect of low-dose antibiotics on
the expression of genes regulating virulence, colonization, motil-
ity, stress response, bioﬁlm formation, gene transfer, secondary
metabolite production, and many other functions. If the sole role
of antibiotics were limited to killing, then no effect of antibi-
otics would be seen below the MIC levels, and the effect would be
neutral. However, it is not the case.
Are eukaryotes involved in this microbial signaling network?
Before the advent of the multicellular organization about 0.5 bil-
lion years ago, the single-celled eukaryotes were probably well-
incorporated into the then-existing microbial ecosystems, with
the corresponding ancient signaling systems, and were also pro-
ducing signaling substances themselves. They probably retained
this capability even after the shift to multicellular organization,
as may be exempliﬁed by some of the ancient eukaryotic organ-
isms having survived until the present days such as sponges which
produce plethora of biologically active compounds, including
antibiotics (Burkholder and Ruetzler, 1969; Laport et al., 2009).
Further developments in multicellular organization in the eukary-
otic world have led to a certain degree of isolation from the
environment and the invention of intra-organismal signaling by
hormones, but interaction and cross-talk with microbiota has
remained an integral part of the lifestyle of eukaryotes. As dis-
cussed above, the microbiota is involved in many aspects of our
metabolism, physiology, immunity, and disease through signaling
to the host, but this is indeed a cross-talk with the microbiota also
listening to the host signals (Burton et al., 2002; Sperandio et al.,
2003; Clarke et al., 2006; Karavolos et al., 2008, 2013).
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The importance of this host–microbe communication has been
exempliﬁed above by the hygiene hypothesis that explains a dra-
matic increase in the number of allergies and asthma in more
developed countries due to limited exposure to environmen-
tal microbiota in the modern world. Another good example of
the malfunctioning host–microbiota communication is the peri-
odontal disease that affects 10–15% of adult population globally
(Petersen and Ogawa, 2012). Although many suspected pathogens
have been implicated in this disease, the underlying cause is more
fundamental and mainly owes to the disrupted host–microbe
interaction (Armitage, 2013; Bartold and Van Dyke, 2013). This
disruption is the result of drastic changes in the lifestyle and
diet imposed by the conversion to farming ca. 10,000 years ago
and especially by the industrial revolution beginning from the
18th century. These changes shifted the oral microbial commu-
nity to a disease-associated conﬁguration (Adler et al., 2013), thus
provoking the host to overly aggressive immune responses that
result in tissue damage and disease progression. As discussed
above, the situation can be somewhat corrected by the use of
low-dose tetracyclines and tetracycline derivatives that suppress
these responses, but this is a temporal solution which does not
tackle the fundamental issue of the disease. The way of solving
this is through reinstatement of oral microbiota from a less sta-
ble and diverse state, which would allow restituting the proper
host–microbiota communication that has been selected and ﬁne-
tuned during prior long-term co-evolution of the host and
microbiota.
Antibiotic signaling network is possibly one of themost ancient
forms of inter-domain communication. It is not a coincidence
that there are so many distinct molecular targets and recep-
tors in eukaryotic cells for which antibiotics serve as ligands.
Although therapeutic potential of this molecular cross-talk is
well-understood and proven in certain pathologies and diseases,
the effect on healthy individuals needs further elaboration. This
is particularly important because the current exposure of humans
to antibiotics, even in generally healthy populations, could be sub-
stantial but the consequences of this are poorly understood. For
example, the phenomenon of the accelerated physiological devel-
opment and tendency to be overweight in modern humans: is it
the same effect of antibiotics similar to the growth promotion in
food animals? The existing regulations require that the level of
antibiotics for instance in meat products entering the human food
chain should be below a certain tolerance level. But how the toler-
ance levels are deﬁned? For example, detection of antibiotics and
sulfonamides in bob veal calf carcasses are performed with the
calf antibiotic and sulfonamide test (CAST) where Bacillus mega-
terium ATCC 9885 is used as the indicator organism (Dey et al.,
2005). In order for a tissue sample to be considered safe, a zone of
inhibition around a swab should be less than 18 mm. Under the
identical incubation conditions antibiotic disks with 8.0 μg of sul-
famethazine produce slightly smaller zones of inhibition, 17 mm
in diameter (Dey et al., 2005). Moreover, the samples may contain
the metabolized antibiotic residues that lost their antimicrobial
activity but may still retain other biotic signaling properties as
discussed in this review.
The use of antibiotics has been predominantly studied from the
antimicrobial activity perspective and focused mostly on infection
control and prevention of antibiotic resistance among pathogens.
The advent and rapid expansion of non-antimicrobial application
of antibiotics may enhance the already existing selective pressure
of antibiotics and contribute to the present antibiotic resistance
problem. Better understanding of biotic functions of antibiotics
may help to design newer antibiotic derivatives with abolished
antimicrobial activities and improved biotic functions.
REFERENCES
Abdul-Hussien, H., Hanemaaijer, R.,
Verheijen, J. H., van Bockel, J. H.,
Geelkerken, R. H., and Lindeman,
J. H. (2009). Doxycycline therapy
for abdominal aneurysm: improved
proteolytic balance through reduced
neutrophil content. J. Vasc. Surg.
49, 741–749. doi: 10.1016/j.jvs.2008.
09.055
Abraham, R. T. (1998). Mammalian tar-
get of rapamycin: immunosuppres-
sive drugs uncover a novel pathway
of cytokine receptor signaling. Curr.
Opin. Immunol. 10, 330–336. doi:
10.1016/S0952-7915(98)80172-6
Adler, C. J., Dobney, K., Weyrich, L. S.,
Kaidonis, J., Walker, A. W., Haak, W.,
et al. (2013). Sequencing ancient cal-
ciﬁed dental plaque shows changes in
oral microbiota with dietary shifts of
the Neolithic and Industrial revolu-
tions. Nat. Genet. 45, 450–455. doi:
10.1038/ng.2536
Alajaji, M., Bowers, M. S., Knackst-
edt, L., and Damaj, M. I. (2013).
Effects of the beta-lactam antibiotic
ceftriaxone on nicotine withdrawal
and nicotine-induced reinstatement
of preference in mice. Psychophar-
macology (Berl.) 228, 419–426. doi:
10.1007/s00213-013-3047-32013
Albert, R. K., Connett, J., Bailey, W. C.,
Casaburi, R., Cooper, J. A. Jr., Criner,
G. J., et al. (2011). Azithromycin
for prevention of exacerbations of
COPD. N. Engl. J. Med. 365, 689–698.
doi: 10.1056/NEJMoa1104623
Altenburg, J., de Graaff, C. S., Stien-
stra, Y., Sloos, J. H., van Haren,
E. H., Koppers, R. J., et al. (2013).
Effect of azithromycin maintenance
treatment on infectious exacerba-
tions among patients with non-cystic
ﬁbrosis bronchiectasis: the BAT ran-
domized controlled trial. JAMA 309,
1251–1259. doi: 10.1001/jama.2013.
1937
Amin, A. R., Attur, M. G., Thakker, G.
D., Patel, P. D., Vyas, P. R., Patel,
R. N., et al. (1996). A novel mecha-
nism of action of tetracyclines: effects
on nitric oxide synthases. Proc. Natl.
Acad. Sci. U.S.A. 93, 14014–14019.
doi: 10.1073/pnas.93.24.14014
Aminov, R. I. (2009). The role
of antibiotics and antibiotic resis-
tance in nature. Environ. Microbiol.
11, 2970–2988. doi: 10.1111/j.1462-
2920.2009.01972.x
Aminov, R. I. (2013). Evolution in
action: dissemination of tet(X) into
pathogenic microbiota. Front. Micro-
biol. 4:192. doi: 10.3389/fmicb.2013.
00192
Amsden, G. W. (2001). Advanced-
generation macrolides: tissue-dir-
ected antibiotics. Int. J. Antimicrob.
Agents 18(Suppl. 1), S11–S15. doi:
10.1016/S0924-8579(01)00410-1
Armitage, G. C. (2013). Learned and
unlearned concepts in periodontal
diagnostics: a 50-year perspective.
Periodontol. 2000 62, 20–36. doi:
10.1111/prd.12006
Barak, S., Liu, F., Hamida, S. B., Yow-
ell, Q. V., Neasta, J., Kharazia, V.,
et al. (2013). Disruption of alcohol-
related memories by mTORC1 inhi-
bitionprevents relapse.Nat. Neurosci.
16, 1111–1117. doi: 10.1038/
nn.3439
Bartold, P. M., and Van Dyke, T.
E. (2013). Periodontitis: a host-
mediated disruption of microbial
homeostasis. Unlearning learned
concepts. Periodontol. 2000 62,
203–217. doi: 10.1111/j.1600-0757.
2012.00450.x
Bartynski, W. S., Tan, H. P., Board-
man, J. F., Shapiro, R., and Marsh,
J. W. (2008). Posterior reversible
encephalopathy syndrome after solid
organ transplantation. AJNR Am.
J. Neuroradiol. 29, 924–930. doi:
10.3174/ajnr.A0960
Baumgart, D. C., MacDonald, J. K.,
and Feagan, B. G. (2008). Tacrolimus
(FK506) for inductionof remission in
refractory ulcerative colitis. Cochrane
Database Syst. Rev. 16, CD007216.
doi: 10.1002/14651858.CD007216
Baumgart, D. C., Pintofﬂ, J. P., Sturm,
A., Wiedenmann, B., and Dig-
nass, A. U. (2006). Tacrolimus is
safe and effective in patients with
severe steroid-refractory or steroid-
dependent inﬂammatory bowel dis-
ease - a long-term follow-up. Am. J.
Gastroenterol. 101, 1048–1056. doi:
10.1111/j.1572-0241.2006.00524.x
Berry, J. D., Shefner, J. M., Conwit,
R., Schoenfeld, D., Keroack, M.,
Felsenstein, D., et al. (2013). Design
and initial results of a multi-phase
randomized trial of ceftriaxone in
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy August 2013 | Volume 4 | Article 241 | 10
“fmicb-04-00241” — 2013/8/16 — 21:17 — page 11 — #11
Aminov Biotic acts of antibiotics
amyotrophic lateral sclerosis. PLoS
ONE 8:e61177. doi: 10.1371/jour-
nal.pone.0061177
Bertrand, X., and Dowzicky, M. J.
(2012). Antimicrobial susceptibility
among gram-negative isolates col-
lected from intensive care units in
North America, Europe, the Asia-
Paciﬁc Rim, Latin America, the Mid-
dle East, andAfrica between 2004 and
2009 as part of the Tigecycline Eval-
uation and Surveillance Trial. Clin.
Ther. 34, 124–137. doi: 10.1016/j.
clinthera.2011.11.023
Bilousova, T. V., Dansie, L., Ngo,
M., Aye, J., Charles, J. R., Ethell,
D. W., et al. (2009). Minocycline
promotes dendritic spine matura-
tion and improves behavioural per-
formance in the fragile X mouse
model. J.Med. Genet. 46, 94–102. doi:
10.1136/jmg.2008.061796
Blasi, F., Bonardi, D., Aliberti,
S., Tarsia, P., Confalonieri, M.,
Amir, O., et al. (2010). Long-term
azithromycin use in patients with
chronic obstructive pulmonary dis-
ease and tracheostomy. Pulm. Phar-
macol. Ther. 23, 200–207. doi:
10.1016/j.pupt.2009.12.002
Bosnar, M., Kragol, G., Koštrun,
S., Vujasinoviæ, I., Bošnjak, B.,
Bencetiæ Mihaljeviæ, V., et al.
(2012). N’-substituted-2’-O,3’-N-
carbonimidoyl bridged macrolides:
novel anti-inﬂammatory macrolides
without antimicrobial activity. J.
Med. Chem. 55, 6111–6123. doi:
10.1021/jm300356u
Brown, E. J., Albers, M. W., Shin, T. B.,
Ichikawa, K., Keith, C. T., Lane,W. S.,
et al. (1994). A mammalian protein
targeted by G1-arresting rapamycin-
receptor complex. Nature 369, 756–
758. doi: 10.1038/369756a0
Burkholder, P. R., and Ruetzler, K.
(1969). Antimicrobial activity of
some marine sponges. Nature 222,
983–984. doi: 10.1038/222983a0
Burton, C. L., Chhabra, S. R., Swift, S.,
Baldwin, T. J., Withers, H., Hill, S.
J., et al. (2002). The growth response
of Escherichia coli to neurotrans-
mitters and related catecholamine
drugs requires a functional enter-
obactin biosynthesis and uptake
system. Infect. Immun. 70, 5913–
5923. doi: 10.1128/IAI.70.11.5913-
5923.2002
Carrell, R. W., and Lomas, D.
A. (1997). Conformational dis-
ease. Lancet 350, 134–138. doi:
10.1016/S0140-6736(97)02073-4
Casha, S., Zygun, D., McGowan, M. D.,
Bains, I., Yong, V. W., and Hurlbert,
R. J. (2012). Results of a phase II
placebo-controlled randomized trial
of minocycline in acute spinal cord
injury. Brain 135, 1224–1236. doi:
10.1093/brain/aws072
Castro, M. M., Tanus-Santos, J.
E., and Gerlach, R. F. (2011).
Matrix metalloproteinases: targets
for doxycycline to prevent the vas-
cular alterations of hypertension.
Pharmacol. Res. 64, 567–572. doi:
10.1016/j.phrs.2011.04.002
Caton, J., and Ryan, M. E. (2011). Clin-
ical studies on the management of
periodontal diseases utilizing suban-
timicrobial dose doxycycline (SDD).
Pharmacol. Res. 63, 114–120. doi:
10.1016/j.phrs.2010.12.003
Chang, K.M., Ryan,M. E., Golub, L.M.,
Ramamurthy, N. S., and McNamara,
T. F. (1996). Local and systemic fac-
tors in periodontal disease increase
matrix-degrading enzyme activities
in rat gingiva: effect of micocycline
therapy. Res. Commun. Mol. Pathol.
Pharmacol. 91, 303–318.
Chen, M., Ona, V. O., Li, M., Ferrante,
R. J., Fink, K. B., Zhu, S., et al. (2000).
Minocycline inhibits caspase-1 and
caspase-3 expression and delays mor-
tality in a transgenic mouse model
of Huntington disease. Nat. Med.
6:797–801. doi: 10.1038/80538
Chen, Z., He, Y., and Wang, Z. J.
(2012). The beta-lactam antibiotic,
ceftriaxone, inhibits the development
of opioid-induced hyperalgesia in
mice. Neurosci. Lett. 509, 69–71. doi:
10.1016/j.neulet.2011.12.029
Choi, Y., Kim, H. S., Shin, K. Y., Kim, E.
M., Kim, M., Kim, H. S., et al. (2007).
Minocycline attenuates neuronal cell
death and improves cognitive impair-
ment in Alzheimer’s disease models.
Neuropsychopharmacology 32, 2393–
2404. doi: 10.1038/sj.npp.1301377
Chu, K., Lee, S. T., Sinn, D. I., Ko,
S. Y., Kim, E. H., Kim, J. M., et al.
(2007). Pharmacological induction
of ischemic tolerance by glutamate
transporter-1 (EAAT2) upregulation.
Stroke 38, 177–182. doi: 10.1161/01.
STR.0000252091.36912.65
Clarke, M. B., Hughes, D. T., Zhu,
C., Boedeker, E. C., and Speran-
dio, V. (2006). The QseC sensor
kinase: a bacterial adrenergic recep-
tor. Proc. Natl. Acad. Sci. U.S.A. 103,
10420–10425. doi: 10.1073/pnas.
0604343103
Cruzado, J. M. (2008). Nonimmuno-
suppressive effects of mammalian
target of rapamycin inhibitors.Trans-
plant. Rev. (Orlando). 22, 73–81. doi:
10.1016/j.trre.2007.09.003
Danbolt, N. C. (2001). Glutamate
uptake. Prog. Neurobiol. 65, 1–105.
doi: 10.1016/S0301-0082(00)00067-8
Dalvi, P. S., Singh, A., Trivedi, H.
R., Ghanchi, F. D., Parmar, D. M.,
and Mistry, S. D. (2011). Effect of
doxycycline in patients of moderate
to severe chronic obstructive pul-
monary disease with stable symp-
toms. Ann. Thorac. Med. 6, 221–226.
doi: 10.4103/1817-1737.84777
Davies, J., Spiegelman, G. B., and
Yim, G. (2006). The world of
subinhibitory antibiotic concentra-
tions. Curr. Opin. Microbiol. 9,
445–453. doi: 10.1016/j.mib.2006.
08.006
Dean,O.M.,Data-Franco, J.,Giorlando,
F., and Berk, M. (2012). Minocy-
cline: therapeutic potential in psychi-
atry. CNS Drugs 26, 391–401. doi:
10.2165/11632000-000000000-00000
Del Rosso, J. Q. (2007). Recently
approved systemic therapies for acne
vulgaris and rosacea. Cutis 80,
113–120.
Dey, B. P., Reamer, R. P., Thaker, N. H.,
and Thaler, A. M. (2005). Calf antibi-
otic and sulfonamide test (CAST) for
screening antibiotic and sulfonamide
residues in calf carcasses. J. AOAC Int.
88, 440–446.
Dezube, B. J., Krown, S. E., Lee, J.
Y., Bauer, K. S., and Aboulaﬁa, D.
M. (2006). Randomized phase II trial
of matrixmetalloproteinase inhibitor
COL-3 in AIDS-related Kaposi’s
sarcoma: an AIDS Malignancy Con-
sortium Study. J. Clin. Oncol. 24,
1389–1394. doi: 10.1200/JCO.2005.
04.2614
Dodel, R., Spottke, A., Gerhard, A.,
Reuss, A., Reinecker, S., Schimke,
N., et al. (2010). Minocycline 1-year
therapy in multiple-system-atrophy:
effect on clinical symptoms and
[(11)C] (R)-PK11195PET (MEMSA-
trial). Mov. Disord. 25, 97–107. doi:
10.1002/mds.22732
Drucker, A. M., and Rosen, C. F. (2011).
Drug-induced photosensitivity: cul-
prit drugs, management and preven-
tion. Drug Saf. 34, 821–837. doi:
10.2165/11592780-000000000-00000
Du, Y., Ma, Z., Lin, S., Dodel, R. C.,
Gao, F., Bales, K. R., et al. (2001).
Minocycline prevents nigrostriatal
dopaminergic neurodegeneration in
the MPTP model of Parkinson’s dis-
ease. Proc. Natl. Acad. Sci. U.S.A.
98, 14669–14674. doi: 10.1073/
pnas.251341998
Elewa, H. F., Hilali, H., Hess, D. C.,
Machado, L. S., and Fagan, S. C.
(2006). Minocycline for short-term
neuroprotection. Pharmacotherapy
26, 515–521. doi: 10.1592/phco.26.
4.515
Encinar, J. A., Mallo, G. V., Mizyrycki,
C., Giono, L., Gonzalez-Ros, J.
M., Rico, M., et al. (2001).
Human p8 is a HMG-I/Y-like pro-
tein with DNA binding activity
enhanced by phosphorylation. J.
Biol. Chem. 276, 2742–2751. doi:
10.1074/jbc.M008594200
Federici, T. J. (2011). Thenon-antibiotic
properties of tetracyclines: clini-
cal potential in ophthalmic disease.
Pharmacol. Res. 64, 614–623. doi:
10.1016/j.phrs.2011.06.013
Forsyth, C. B., Shannon, K. M., Kor-
dower, J. H., Voigt, R. M., Shaikh,
M., Jaglin, J. A., et al. (2011).
Increased intestinal permeability cor-
relates with sigmoid mucosa alpha-
synuclein staining and endotoxin
exposuremarkers in early Parkinson’s
disease. PLoS ONE 6:e28032. doi:
10.1371/journal.pone.0028032
Gabler, W. L., and Creamer, H. R.
(1991). Suppression of human neu-
trophil functions by tetracyclines. J.
Periodontal Res. 26, 52–58. doi:
10.1111/j.1600-0765.1991.tb01626.x
Gao, F., Li, M., Liu, Y., Gao, C.,
Wen, S., and Tang, L. (2012). Intesti-
nal dysbacteriosis induces changes
of T lymphocyte subpopulations in
Peyer’s patches of mice and ori-
ents the immune response towards
humoral immunity.GutPathog. 4, 19.
doi: 10.1186/1757-4749-4-19
Garrido-Mesa, N., Zarzuelo, A., and
Gálvez, J. (2013). Minocycline: far
beyond an antibiotic. Br. J. Pharma-
col. 169, 337–352. doi: 10.1111/bph.
12139
Glatz, M., and Hofbauer, G. F.
(2012). Phototoxic and photoaller-
gic cutaneous drug reactions. Chem.
Immunol. Allergy 97, 167–179. doi:
10.1159/000335630
Gluud, C., Als-Nielsen, B., Damgaard,
M., Fischer Hansen, J., Hansen, S.,
Helø, O. H., et al. (2008). Clar-
ithromycin for 2 weeks for stable
coronary heart disease: 6-year follow-
up of the CLARICOR randomized
trial and updated meta-analysis of
antibiotics for coronary heart dis-
ease. Cardiology 111, 280–287. doi:
10.1159/000128994
Golub, L. M. (2011). Introduction
and background. Pharmacol. Res.
63, 99–101. doi: 10.1016/j.phrs.2010.
10.003
Golub, L. M., Lee, H. M., Lehrer,
G., Nemiroff, A., McNamara, T. F.,
Kaplan, R., et al. (1983). Minocy-
cline reduces gingival collagenolytic
activity during diabetes. Preliminary
observations and a proposed new
mechanism of action. J. Periodon-
tal Res. 18, 516–526. doi: 10.1111/j.
1600-0765.1983.tb00388.x
Golub, L. M., McNamara, T. F.,
D’Angelo, G., Greenwald, R. A.,
and Ramamurthy, N. S. (1987).
A non-antibacterial chemically-
modiﬁed tetracycline inhibits
mammalian collagenase activity.
www.frontiersin.org August 2013 | Volume 4 | Article 241 | 11
“fmicb-04-00241” — 2013/8/16 — 21:17 — page 12 — #12
Aminov Biotic acts of antibiotics
J. Dent. Res. 66, 1310–1314.
doi: 10.1177/002203458706600
80401
Golub, L. M., Ramamurthy, N. S.,
McNamara, T. F., Greenwald, R. A.,
andRifkin, B. R. (1991). Tetracyclines
inhibit connective tissue breakdown:
new therapeutic implications for an
old family of drugs. Crit. Rev. Oral
Biol. Med. 2, 297–321.
Good, J. T. Jr., Rollins, D. R., and
Martin, R. J. (2012). Macrolides
in the treatment of asthma. Curr.
Opin. Pulm. Med. 18, 76–84. doi:
10.1097/MCP.0b013e32834daff8
Gordon, P. H., Moore, D. H., Miller,
R. G., Florence, J. M., Verheijde, J.
L., Doorish, C., et al. (2007). Efﬁ-
cacy of minocycline in patients with
amyotrophic lateral sclerosis: a phase
III randomised trial. Lancet Neurol.
6, 1045–1053. doi: 10.1016/S1474-
4422(07)70270-3
Goruppi, S., Patten, R. D., Force, T., and
Kyriakis, J. M. (2007). Helix-loop-
helix protein p8, a transcriptional
regulator required for cardiomyocyte
hypertrophy and cardiac ﬁbroblast
matrix metalloprotease induction.
Mol. Cell. Biol. 27, 993–1006. doi:
10.1128/MCB.00996-06
Greenwald, R. A. (2011). The road for-
ward: the scientiﬁc basis for tetracy-
cline treatment of arthritic disorders.
Pharmacol. Res. 64, 610–613. doi:
10.1016/j.phrs.2011.06.010
Grenier, D., Plamondon, P., Sorsa,
T., Lee, H. M., McNamara,
T., Ramamurthy, N. S., et al.
(2002). Inhibition of proteolytic,
serpinolytic, and progelatinase-b
activation activities of periodon-
topathogens by doxycycline and the
non-antimicrobial chemically modi-
ﬁed tetracycline derivatives. J. Peri-
odontol. 73, 79–85. doi: 10.1902/
jop.2002.73.1.79
Gu, Y., Lee, H. M., Sorsa, T., Salmi-
nen, A., Ryan, M. E., Slepian, M. J.,
et al. (2011). Non-antibacterial tetra-
cyclines modulate mediators of peri-
odontitis and atherosclerotic cardio-
vascular disease: a mechanistic link
between local and systemic inﬂam-
mation. Pharmacol. Res. 64, 573–579.
doi: 10.1016/j.phrs.2011.06.023
Gu, Y., Walker, C., Ryan, M. E., Payne,
J. B., and Golub, L. M. (2012).
Non-antibacterial tetracycline for-
mulations: clinical applications in
dentistry and medicine. J. Oral
Microbiol. 4. doi: 10.3402/jom.v4i0.
19227
Gunduz, O., Oltulu, C., and Ulugol,
A. (2011). Role of GLT-1 transporter
activation in prevention of cannabi-
noid tolerance by theβ-lactamantibi-
otic, ceftriaxone, in mice. Pharmacol.
Biochem. Behav. 99, 100–103. doi:
10.1016/j.pbb.2011.04.012
Gurk-Turner, C., Manitpisitkul, W.,
and Cooper, M. (2012). A compre-
hensive review of everolimus clinical
reports: a new mammalian target
of rapamycin inhibitor. Transplan-
tation 94, 659–668. doi: 10.1097/
TP.0b013e31825b411c
Hammerstrom, A. E., Howell, J.,
Gulbis, A., Rondon, G., Cham-
plin, R. E., and Popat, U. (2013).
Tacrolimus-associated posterior
reversible encephalopathy syndrome
in hematopoietic allogeneic stem cell
transplantation. Am. J. Hematol. 88,
301–305. doi: 10.1002/ajh.23402
Hanemaaijer, R., Sorsa, T., Kontti-
nen, Y. T., Ding, Y., Sutinen, M.,
Visser, H., et al. (1997). Matrix
metalloproteinase-8 is expressed in
rheumatoid synovial ﬁbroblasts and
endothelial cells. Regulation by
tumor necrosis factor-alpha and
doxycycline. J. Biol. Chem. 272,
31504–31509. doi: 10.1074/jbc.272.
50.31504
Harry, G. J. (2013). Microglia during
development and aging. Pharmacol.
Ther. doi: 10.1016/j.pharmthera.
2013.04.013 [Epub ahead of
print].
Henneman, A., and Thornby, K. A.
(2012). Risk of hypotension with
concomitant use of calcium-channel
blockers and macrolide antibiotics.
Am. J. Health Syst. Pharm. 69, 1038–
1043. doi: 10.2146/ajhp110486
Hishikari, K., Watanabe, R., Ogawa, M.,
Suzuki, J., Masumura, M., Shimizu,
T., et al. (2010). Early treatment
with clarithromycin attenuates rat
autoimmune myocarditis via inhi-
bition of matrix metalloproteinase
activity. Heart 96, 523–527. doi:
10.1136/hrt.2009.188094
Ho, S., Clipstone, N., Timmer-
mann, L., Northrop, J., Graef, I.,
Fiorentino, D., et al. (1996). The
mechanism of action of cyclosporin
A and FK506. Clin. Immunol.
Immunopathol. 80:S40–S45. doi:
10.1006/clin.1996.0140
Hodnett, P., Coyle, J., O’Regan, K.,
Maher, M. M., and Fanning, N.
(2009). PRES (posterior reversible
encephalopathy syndrome), a rare
complication of tacrolimus therapy.
Emerg. Radiol. 16, 493–496. doi:
10.1007/s10140-008-0782-6
Hoffmeister, A., Ropolo, A., Vasseur,
S., Mallo, G. V., Bodeker, H.,
Ritz-Laser, B., et al. (2002). The
HMG-I/Y-related protein p8 binds
to p300 and Pax2 trans-activation
domain-interacting protein to reg-
ulate the trans-activation activ-
ity of the Pax2A and Pax2B
transcription factors on the glucagon
gene promoter. J. Biol. Chem.
277, 22314–22319. doi: 10.1074/jbc.
M201657200
Holloway, R. A., and Donnelly, L.
E. (2013). Immunopathogenesis of
chronic obstructive pulmonary dis-
ease. Curr. Opin. Pulm. Med.
19, 95–102. doi: 10.1097/MCP.
0b013e32835cfff5
Huttner, B., Jones, M., Rubin, M. A.,
Neuhauser, M. M., Gundlapalli, A.,
and Samore, M. (2012). Drugs of
last resort? The use of polymyxins
and tigecycline at US Veterans Affairs
medical centers, 2005–2010. PLoS
ONE 7:e36649. doi: 10.1371/jour-
nal.pone.0036649
Ištuk, Z. M., Cikoš,A., Gembarovski, D.,
Lazarevski, G.,Diloviæ, I.,Matkoviæ-
Èalogoviæ, D., et al. (2011). Novel
9a,11-bridged azalides: one-pot syn-
thesis of N’-substituted 2-imino-1,3-
oxazolidines condensed to an azalide
aglycone. Bioorg. Med. Chem. 19,
556–566. doi: 10.1016/j.bmc.2010.
10.061
Jin, W. J., Feng, S. W., Feng, Z., Lu, S.
M., Qi, T., and Qian, Y. N. (2013).
Minocycline improves postopera-
tive cognitive impairment in aged
mice by inhibiting astrocytic acti-
vation. Neuroreport doi: 10.1097/
WNR.0b013e3283629195 [Epub
ahead of print].
Joks, R., and Durkin, H. G. (2011).
Effect of tetracyclines on IgE aller-
gic responses and asthma. Recent
Pat. Inﬂamm. Allergy Drug Dis-
cov. 5, 221–228. doi: 10.2174/
187221311797264919
Jonat, C., Chung, F. Z., and Baragi,
V. M. (1996). Transcriptional down-
regulation of stromelysin by tetra-
cycline. J. Cell. Biochem. 60,
341–347. doi: 10.1002/(SICI)1097-
4644(19960301)60:3
Kalivas, P. W., Lalumiere, R. T., Knack-
stedt, L., and Shen, H. (2009).
Glutamate transmission in addiction.
Neuropharmacology 56(Suppl. 1),
169–173. doi: 10.1016/j.neuropharm.
2008.07.011
Karavolos, M. H., Spencer, H., Bul-
mer, D. M., Thompson, A., Winzer,
K., Williams, P., et al. (2008).
Adrenaline modulates the global
transcriptional proﬁle of Salmonella
revealing a role in the antimicro-
bial peptide and oxidative stress
resistance responses. BMC Genomics
9:458. doi: 10.1186/1471-2164-
9-458
Karavolos, M. H., Winzer, K., Williams,
P., and Khan, C. M. (2013).
Pathogen espionage: multiple bac-
terial adrenergic sensors eavesdrop
on host communication systems.
Mol. Microbiol. 87, 455–465. doi:
10.1111/mmi.12110
Kato, T. A., Watabe, M., Tsuboi, S.,
Ishikawa, K., Hashiya, K., Monji,
A., et al. (2012). Minocycline
modulates human social decision-
making: possible impact of microglia
on personality-oriented social
behaviours. PLoS ONE 7:e40461.
doi: 10.1371/journal.pone.0040461
Kino, T., Hatanaka, H., Hashimoto,
M., Nishiyama, M., Goto, T.,
Okuhara, M., et al. (1987). FK-506,
a novel immunosuppressant isolated
from a Streptomyces. I. Fermenta-
tion, isolation, and physico-chemical
and biological characteristics. J.
Antibiot. (Tokyo) 40, 1249–1255. doi:
10.7164/antibiotics.40.1249
Knackstedt, L. A., Melendez, R. I.,
and Kalivas, P. W. (2010). Ceftriax-
one restores glutamate homeostasis
and prevents relapse to cocaine seek-
ing. Biol. Psychiatry 67, 81–84. doi:
10.1016/j.biopsych.2009.07.018
Kobayashi, Y., Wada, H., Rossios, C.,
Takagi, D., Higaki, M., Mikura,
S., et al. (2013). A novel macrolide
solithromycin exerts superior anti-
inﬂammatory effect via NF-κB inhi-
bition. J. Pharmacol. Exp. Ther. 345,
76–84. doi: 10.1124/jpet.112.200733
Kong, F., Chen, S., Cheng, Y., Ma, L., Lu,
H., Zhang, H., et al. (2013). Minocy-
cline attenuates cognitive impair-
ment induced by isoﬂurane anes-
thesia in aged rats. PLoS ONE
8:e61385. doi: 10.1371/journal.pone.
0061385
Kraus, R. L., Pasieczny, R., Lariosa-
Willingham, K., Turner, M. S.,
Jiang, A., and Trauger, J. W. (2005).
Antioxidant properties of minocy-
cline: neuroprotection in an oxidative
stress assay and direct radical-
scavenging activity. J. Neurochem.
94, 819–827. doi: 10.1111/j.1471-
4159.2005.03219.x
Kudoh, S., Uetake, T., Hagiwara,
K., Hirayama, M., Hus, L. H.,
Kimura, H., et al. (1987). Clin-
ical effects of low-dose long-term
erythromycin chemotherapy on dif-
fuse panbronchiolitis. Nihon Kyobu
Shikkan Gakkai Zasshi 25, 632–642.
Lai, A. Y., and Todd, K. G. (2006).
Hypoxia-activated microglial media-
tors of neuronal survival are differen-
tially regulated by tetracyclines. Glia
53, 809–816. doi: 10.1002/glia.20335
Lai, P. C., Huang, Y. T., Wu, C. C.,
Lai, C. J., Wang, P. J., and Chiu,
T. H. (2011). Ceftriaxone attenu-
ates hypoxic-ischemic brain injury in
neonatal rats. J. Biomed. Sci. 18, 69.
doi: 10.1186/1423-0127-18-69
Lamming, D. W., Ye, L., Sabatini, D. M.,
and Baur, J. A. (2013). Rapalogs and
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy August 2013 | Volume 4 | Article 241 | 12
“fmicb-04-00241” — 2013/8/16 — 21:17 — page 13 — #13
Aminov Biotic acts of antibiotics
mTOR inhibitors as anti-aging thera-
peutics. J. Clin. Invest. 123, 980–989.
doi: 10.1172/JCI64099
Laport,M. S., Santos, O. C., and Muricy,
G. (2009). Marine sponges: potential
sources of new antimicrobial drugs.
Curr. Pharm. Biotechnol. 10, 86–105.
doi: 10.2174/138920109787048625
Ledeboer, A., Sloane, E. M., Milligan,
E. D., Frank, M. G., Mahony, J. H.,
Maier, S. F., et al. (2005). Minocy-
cline attenuates mechanical allody-
nia and proinﬂammatory cytokine
expression in rat models of pain
facilitation. Pain 115, 71–83. doi:
10.1016/j.pain.2005.02.009
Leiva, M., Ruiz-Bravo, A., and
Jiménez-Valera, M. (2008a). Effects
of telithromycin in in vitro and in
vivo models of lipopolysaccharide-
induced airway inﬂammation. Chest
134, 20–29. doi: 10.1378/chest.07-
3056
Leiva, M., Ruiz-Bravo, A., Moreno,
E., and Jiménez-Valera, M. (2008b).
Telithromycin inhibits the produc-
tion of proinﬂammatory mediators
and the activation of NF-kappaB
in in vitro-stimulated murine cells.
FEMS Immunol. Med. Microbiol.
53, 343–350. doi: 10.1111/j.1574-
695X.2008.00424.x
Levkovitz,Y.,Mendlovich, S., Riwkes, S.,
Braw, Y., Levkovitch-Verbin, H., Gal,
G., et al. (2010). A double-blind, ran-
domized study of minocycline for the
treatment of negative and cognitive
symptoms in early-phase schizophre-
nia. J. Clin. Psychiatry 71, 138–149.
doi: 10.4088/JCP.08m04666yel
Lewerenz, J., Albrecht, P., Tien, M.
L., Henke, N., Karumbayaram, S.,
Kornblum, H. I., et al. (2009). Induc-
tion of Nrf2 and xCT are involved
in the action of the neuroprotec-
tive antibiotic ceftriaxone in vitro.
J. Neurochem. 111, 332–343. doi:
10.1111/j.1471-4159.2009.06347.x
Li, S. Y., Xia, L. X., Zhao, Y. L., Yang, L.,
Chen, Y. L., Wang, J. T., et al. (2013).
Minocycline mitigates isoﬂurane-
induced cognitive impairment in
aged rats. Brain Res. 1496, 84–93. doi:
10.1016/j.brainres.2012.12.025
Linares, J. F., Gustafsson, I., Baquero, F.,
andMartinez, J. L. (2006). Antibiotics
as intermicrobial signalling agents
instead of weapons. Proc. Natl. Acad.
Sci. U.S.A. 103, 19484–19489. doi:
10.1073/pnas.0608949103
Lokeshwar, B. L. (1999). MMP inhi-
bition in prostate cancer. Ann. N.
Y. Acad Sci. 878, 271–289. doi:
10.1111/j.1749-6632.1999.tb07690.x
Lokeshwar, B. L. (2011). Chemi-
cally modiﬁed non-antimicrobial
tetracyclines are multifunctional
drugs against advanced cancers.
Pharmacol. Res. 63, 146–150. doi:
10.1016/j.phrs.2010.11.003
Lutz, L., Pereira, D. C., Paiva, R.
M., Zavascki, A. P., and Barth,
A. L. (2012). Macrolides decrease
theminimal inhibitory concentration
of anti-pseudomonal agents against
Pseudomonas aeruginosa from cys-
tic ﬁbrosis patients in bioﬁlm. BMC
Microbiol. 12:196. doi: 10.1186/1471-
2180-12-196
Mallo, G. V., Fiedler, F., Calvo, E. L.,
Ortiz, E. M., Vasseur, S., Keim, V.,
et al. (1997). Cloning and expres-
sion of the rat p8 cDNA, a new
gene activated in pancreas during the
acute phase of pancreatitis, pancre-
atic development, and regeneration,
and which promotes cellular growth.
J. Biol. Chem. 272, 32360–32369. doi:
10.1074/jbc.272.51.32360
Malmo, C., Vilasi, S., Iannuzzi,
C., Tacchi, S., Cametti, C.,
Irace, G., et al. (2006). Tetracy-
cline inhibits W7FW14F apomyo-
globin ﬁbril extension and keeps the
amyloid protein in a pre-ﬁbrillar,
highly cytotoxic state. FASEB J. 20,
346–347.
Mannino, D. M., and Buist, A. S. (2007).
Global burden of COPD: risk factors,
prevalence, and future trends. Lancet
370, 765–773. doi: 10.1016/S0140-
6736(07)61380-4
Maragakis, N. J., and Rothstein, J.
D. (2001). Glutamate transporters
in neurologic disease. Arch. Neu-
rol. 58, 365–370. doi: 10.1001/arch-
neur.58.3.365
Marchand, F., Tsantoulas, C., Singh,
D., Grist, J., Clark, A. K., Brad-
bury, E. J., et al. (2009). Effects of
Etanercept and Minocycline in a rat
model of spinal cord injury. Eur.
J. Pain 13, 673–681. doi: 10.1016/j.
ejpain.2008.08.001
Martínez, J. L. (2008). Antibiotics and
antibiotic resistance genes in natural
environments. Science 321, 365–367.
doi: 10.1126/science.1159483
Melzer, N., Meuth, S. G., Torres-
Salazar, D., Bittner, S., Zozulya, A.
L., Weidenfeller, C., et al. (2008).
A beta-lactam antibiotic dampens
excitotoxic inﬂammatory CNS dam-
age in a mouse model of multiple
sclerosis. PLoS ONE 3:e3149. doi:
10.1371/journal.pone.0003149
Metz, L. M., Zhang, Y., Yeung, M.,
Patry, D. G., Bell, R. B., Stoian, C.
A., et al. (2004). Minocycline reduces
gadolinium-enhancing magnetic res-
onance imaging lesions in multiple
sclerosis. Ann. Neurol. 55, 756. doi:
10.1002/ana.20111
Million Passe, C. M., White, C. R.,
King, M. W., Quirk, P. L., Iovanna,
J. L., and Quirk, C. C. (2008). Loss
of the protein NUPR1 (p8) leads
to delayed LHB expression, delayed
ovarian maturation, and testicular
development of a sertoli-cell-only
syndrome-like phenotype in mice.
Biol. Reprod. 79, 598–607. doi:
10.1095/biolreprod.108.068304
Miyamoto, A.,Wake, H.,Moorhouse, A.
J., and Nabekura, J. (2013). Microglia
and synapse interactions: ﬁne tun-
ing neural circuits and candidate
molecules. Front. Cell. Neurosci. 7:70.
doi: 10.3389/fncel.2013.00070
Miyaoka, T. (2008). Clinical poten-
tial of minocycline for schizophre-
nia. CNS Neurol. Disord. Drug
Targets 7, 376–381. doi: 10.2174/
187152708786441858
Miyaoka, T., Wake, R., Furuya, M.,
Liaury, K., Ieda, M., Kawakami,
K., et al. (2012). Minocycline as
adjunctive therapy for patients with
unipolar psychotic depression: an
open-label study. Prog. Neuropsy-
chopharmacol. Biol. Psychiatry 37,
222–226. doi: 10.1016/j.pnpbp.2012.
02.002
Monte, S. V., Prescott, W. A., Johnson,
K. K., Kuhman, L., and Paladino, J. A.
(2008). Safety of ceftriaxone sodium
at extremes of age. Expert Opin.
Drug Saf. 7, 515–523. doi: 10.1517/
14740338.7.5.515
Mor, F., and Cohen, I. R. (2013).
Beta-lactam antibiotics modulate
T-cell functions and gene expres-
sion via covalent binding to cel-
lular albumin. Proc. Natl. Acad.
Sci. U.S.A. 110, 2981–2986. doi:
10.1073/pnas.1215722110
Morimura, T., Hashiba, M., Kameda,
H., Takami, M., Takahama, H.,
Ohshige, M., et al. (2008). Iden-
tiﬁcation of macrolide antibiotic-
binding human p8 protein. J.
Antibiot. (Tokyo) 61, 291–296. doi:
10.1038/ja.2008.41
Mrowietz, U. (1992). The enigma of
cyclosporin A treatment in psoriasis:
systemic efﬁcacy versus topical non-
responsiveness. Acta. Derm. Venereol.
72, 321–316.
Mrowietz, U. (1999). Macrolide
immunosuppressants. Eur. J. Derma-
tol. 9, 346–351.
Mutak, S. (2007). Azalides from
azithromycin to new azalide deriva-
tives. J. Antibiot. (Tokyo) 60, 85–122.
doi: 10.1038/ja.2007.10
Nagai, H., Shishido, H., Yoneda,
R., Yamaguchi, E., Tamura, A.,
and Kurashima, A. (1991). Long-
term low-dose administration of
erythromycin to patients with dif-
fuse panbronchiolitis. Respiration 58,
145–149. doi: 10.1159/000195915
Nakajima, T., Hishikari, K., Ogawa,
M., Watanabe, R., Suzuki, J.,
Nagashima, A., et al. (2010). Clar-
ithromycin attenuates myocardial
ischemia-reperfusion injury. Expert
Opin. Ther. Targets 14, 881–893. doi:
10.1517/14728222.2010.502890
Nakasujja, N., Miyahara, S., Evans,
S., Lee, A., Musisi, S., Katabira,
E., et al. (2013). Randomized trial
of minocycline in the treatment
of HIV-associated cognitive impair-
ment. Neurology 80, 196–202. doi:
10.1212/WNL.0b013e31827b9121
Nizzardo, M., Nardini, M., Ronchi,
D., Salani, S., Donadoni, C., For-
tunato, F., et al. (2011). Beta-lactam
antibiotic offers neuroprotection in
a spinal muscular atrophy model
by multiple mechanisms. Exp. Neu-
rol. 229, 214–225. doi: 10.1016/j.
expneurol.2011.01.017
Orsucci, D., Calsolaro, V., Mancuso,
M., and Siciliano, G. (2009). Neu-
roprotective effects of tetracyclines:
molecular targets, animalmodels and
human disease. CNS Neurol. Dis-
ord. Drug Targets. 8, 222–231. doi:
10.2174/187152709788680689
Payne, J. B., and Golub, L. M. (2011).
Using tetracyclines to treat osteo-
porotic/osteopenic bone loss: from
the basic science laboratory to the
clinic. Pharmacol. Res. 63, 121–129.
doi: 10.1016/j.phrs.2010.10.006
Payne, J. B., Golub, L. M., Stoner,
J. A., Lee, H. M., Reinhardt, R.
A., Sorsa, T., et al. (2011). The
effect of subantimicrobial-dose-
doxycycline periodontal therapy
on serum biomarkers of systemic
inﬂammation: a randomized,
double-masked, placebo-controlled
clinical trial. J. Am. Dent. Assoc. 142,
262–273.
Periti, P., Mazzei, T., Mini, E., and
Novelli, A. (1993). Adverse effects
of macrolide antibacterials. Drug Saf.
9, 346–364. doi: 10.2165/00002018-
199309050-00004
Perrins, R. D., Cecere, G., Pater-
son, I., and Marriott, G. (2008).
Synthetic mimetics of actin-binding
macrolides: rational design of actin-
targeted drugs. Chem. Biol. 15,
287–294. doi: 10.1016/j.chembiol.
2008.01.010
Petersen, P. E., and Ogawa, H. (2012).
The global burden of periodontal
disease: towards integration with
chronic disease prevention and con-
trol. Periodontol 2000 60, 15–39. doi:
10.1111/j.1600-0757.2011.00425.x
Powers, R. W. III, Kaeberlein, M., Cald-
well, S. D., Kennedy, B. K., and Fields,
S. (2006). Extension of chronolog-
ical life span in yeast by decreased
TOR pathway signalling. Genes Dev.
20, 174–184. doi: 10.1101/gad.
1381406
www.frontiersin.org August 2013 | Volume 4 | Article 241 | 13
“fmicb-04-00241” — 2013/8/16 — 21:17 — page 14 — #14
Aminov Biotic acts of antibiotics
Qiu, Z., and MacRae, T. H. (2007).
Developmentally regulated synthesis
of p8, a stress-associated transcrip-
tion cofactor, in diapause-destined
embryos of Artemia franciscana. Cell
Stress Chaperones 12, 255–264. doi:
10.1379/CSC-275.1
Qrunﬂeh, A. M., Alazizi, A., and
Sari, Y. (2013). Ceftriaxone, a
beta-lactam antibiotic, attenuates
relapse-like ethanol-drinking behav-
ior in alcohol-preferring rats. J. Psy-
chopharmacol. 27, 541–549. doi:
10.1177/0269881113482529
Rao, P. S., and Sari,Y. (2012). Glutamate
transporter 1: target for the treat-
ment of alcohol dependence. Curr.
Med. Chem. 19, 5148–5156. doi:
10.2174/092986712803530511
Rasmussen, B., Unterwald, E. M., and
Rawls, S.M. (2011). Glutamate trans-
porter subtype 1 (GLT-1) activator
ceftriaxone attenuates amphetamine-
induced hyperactivity and behavioral
sensitization in rats. Drug Alcohol
Depend. 118, 484–488. doi: 10.1016/j.
drugalcdep.2011.03.022
Rath, T. (2013). Tacrolimus in
transplant rejection. Expert Opin.
Pharmacother. 14, 115–122. doi:
10.1517/14656566.2013.751374
Rawls, S. M., Baron, D. A., and
Kim, J. (2010a). Beta-Lactam antibi-
otic inhibits development of mor-
phine physical dependence in rats.
Behav. Pharmacol. 21, 161–164. doi:
10.1097/FBP.0b013e328337be10
Rawls, S. M., Zielinski, M., Patel,
H., Sacavage, S., Baron, D. A.,
and Patel, D. (2010b). Beta-lactam
antibiotic reduces morphine anal-
gesic tolerance in rats through GLT-1
transporter activation. Drug Alco-
hol Depend. 107, 261–263. doi:
10.1016/j.drugalcdep.2009.10.010
Rawls, S. M., Cavallo, F., Capasso,
A., Ding, Z., and Raffa, R. B.
(2008). The beta-lactam antibiotic
ceftriaxone inhibits physical depen-
dence and abstinence-induced with-
drawal from cocaine, amphetamine,
methamphetamine, and clorazepate
in planarians. Eur. J. Pharma-
col. 584, 278–284. doi: 10.1016/j.
ejphar.2008.02.018
Richards, C., Pantanowitz, L., and
Dezube, B. J. (2011). Antimicrobial
and non-antimicrobial tetracyclines
in human cancer trials. Pharmacol.
Res. 63, 151–156. doi: 10.1016/j.phrs.
2010.10.008
Romero, D., Traxler, M. F., López, D.,
and Kolter, R. (2011). Antibiotics
as signal molecules.Chem Rev. 111,
5492–5505. doi: 10.1021/cr2000509
Rothstein, J. D., Patel, S., Regan,
M. R., Haenggeli, C., Huang, Y.
H., Bergles, D. E., et al. (2005).
Beta-lactam antibiotics offer neuro-
protection by increasing glutamate
transporter expression. Nature 433,
73–77. doi: 10.1038/nature03180
Rotschafer, S. E., Trujillo, M. S., Dan-
sie, L. E., Ethell, I. M., and Razak,
K. A. (2012). Minocycline treat-
ment reverses ultrasonic vocaliza-
tion production deﬁcit in a mouse
model of Fragile X Syndrome. Brain
Res. 1439, 7–14. doi: 10.1016/j.
brainres.2011.12.041
Roy, S. K., Kendrick, D., Sadowitz, B.
D., and Gatto, L. (2011). Jack of all
trades: pleiotropy and the application
of chemically modiﬁed tetracycline-
3 in sepsis and the acute respira-
tory distress syndrome. Pharmacol.
Res. 64, 580–589. doi: 10.1016/j.
phrs.2011.06.012
Sabers, C. J., Martin, M. M., Brunn,
G. J., Williams, J. M., Dumont, F.
J., Wiederrecht, G., et al. (1995).
Isolation of a protein target of
the FKBP12-rapamycin complex in
mammalian cells. J. Biol. Chem. 270,
815–822. doi: 10.1074/jbc.270.2.815
Salo, T., Soini, Y., Oiva, J., Kariyli-
talo, Nissinen, A., Biancari, F., et al.
(2006). Chemically modiﬁed tetracy-
clines (CMT-3 and CMT-8) enable
control of the pathologic remodella-
tion of human aortic valve stenosis
via MMP-9 and VEGF inhibition.
Int. J. Cardiol. 111, 358–364. doi:
10.1016/j.ijcard.2005.07.042
Sánchez, A. R., Rogers, R. S.
III, and Sheridan, P. J. (2004).
Tetracycline and other tetracycline-
derivative staining of the teeth
and oral cavity. Int. J. Dermatol.
43, 709–715. doi: 10.1111/j.1365-
4632.2004.02108.x
Sari, Y., Franklin, K. M., Alazizi, A.,
Rao, P. S., and Bell, R. L. (2013).
Effects of ceftriaxone on the acqui-
sition and maintenance of ethanol
drinking in peri-adolescent and adult
female alcohol-preferring (P) rats.
Neuroscience 241, 229–238. doi:
10.1016/j.neuroscience.2013.03.016
Sari, Y., Sakai, M., Weedman, J.
M., Rebec, G. V., and Bell, R.
L. (2011). Ceftriaxone, a beta-
lactam antibiotic, reduces ethanol
consumption in alcohol-preferring
rats. Alcohol Alcohol. 46, 239–234.
doi: 10.1093/alcalc/agr023
Sari, Y., Smith, K. D., Ali, P.
K., and Rebec, G. V. (2009).
Upregulation of GLT1 attenu-
ates cue-induced reinstatement
of cocaine-seeking behavior in rats.
J. Neurosci. 29, 9239–9243. doi:
10.1523/JNEUROSCI.1746-09.2009
Sbardella, D., Fasciglione, G. F., Gioia,
M., Ciaccio, C., Tundo, G. R.,
Marini, S., et al. (2012). Human
matrix metalloproteinases: an ubiq-
uitarian class of enzymes involved in
several pathological processes. Mol.
Aspects Med. 33, 119–208. doi:
10.1016/j.mam.2011.10.015
Schultz, M. J. (2004). Macrolide
activities beyond their antimicrobial
effects: macrolides in diffuse pan-
bronchiolitis and cystic ﬁbrosis. J.
Antimicrob. Chemother. 54, 21–28.
doi: 10.1093/jac/dkh309
Schwarz, H., Hickey, C., Zimmerman,
C.,Mazzoni, P.,Moskowitz, C., Rosas,
D., et al. (2010). A futility study of
minocycline in Huntington’s disease.
Mov. Disord. 25, 2219–2224. doi:
10.1002/mds.23236
Seemungal, T. A. R., Wilkinson, T.
M. A., Hurst, J. R., Perera, W. R.,
Sapsford, R. J., and Wedzicha, J.
A. (2008). Long-term erythromycin
therapy is associated with decreased
chronic obstructive pulmonary dis-
ease exacerbations. Am. J. Respir.
Crit. Care Med. 178, 1139–1147. doi:
10.1164/rccm.200801-145OC
Serisier, D. J., Martin, M. L.,
McGuckin, M. A., Lourie, R.,
Chen, A. C., Brain, B., et al.
(2013). Effect of long-term, low-
dose erythromycin on pulmonary
exacerbations among patients with
non-cystic ﬁbrosis bronchiectasis:
the BLESS randomized controlled
trial. JAMA 309, 1260–1267. doi:
10.1001/jama.2013.2290
Sewell, K. L., Breedveld, F., Fur-
rie, E., O’Brien, J., Brinckerhoff,
C., Dynesius-Trentham, R., et al.
(1996). The effect of minocycline in
rat models of inﬂammatory arthritis:
correlation of arthritis suppression
with enhanced T cell calcium ﬂux.
Cell. Immunol. 167, 195–204. doi:
10.1006/cimm.1996.0027
Shalviri, G., Youseﬁan, S., and Gho-
lami, K. (2012). Adverse events
induced by ceftriaxone: a 10-year
review of reported cases to Iranian
Pharmacovigilance Centre. J. Clin.
Pharm. Ther. 37, 448–451. doi:
10.1111/j.1365-2710.2011.01321.x
Shigeri, Y., Seal, R. P., and Shimamoto,
K. (2004). Molecular pharmacology
of glutamate transporters, EAATs
and VGLUTs. Brain Res. Rev. 45,
250–265. doi: 10.1016/j.brainresrev.
2004.04.004
Siller, S. S., and Broadie, K. (2012).
Matrix metalloproteinases and
minocycline: therapeutic avenues
for fragile X syndrome. Neural Plast.
2012, 124548. doi: 10.1155/2012/
124548
Simoens, S., Laekeman, G., and
Decramer, M. (2013). Prevent-
ing COPD exacerbations with
macrolides: a review and budget
impact analysis. Respir. Med. 107,
637–648. doi: 10.1016/j.rmed.
2012.12.019
Singh, P. K., Schaefer, A. L., Parsek, M.
R., Moninger, T. O., Welsh, M. J., and
Greenberg, E. P. (2000). Quorum-
sensing signals indicate that cystic
ﬁbrosis lungs are infected with bac-
terial bioﬁlms. Nature 407, 762–764.
doi: 10.1038/35037627
Sirangelo, I., and Irace, G. (2010).
Inhibition of aggregate formation as
therapeutic target in protein mis-
folding diseases: effect of tetracy-
cline and trehalose. Expert Opin.
Ther. Targets. 14, 1311–1321. doi:
10.1517/14728222.2010.531012
Smith, G. N. Jr., Mickler, E. A., Hasty,
K. A., and Brandt, K. D. (1999).
Speciﬁcity of inhibition of matrix
metalloproteinase activity by doxy-
cycline: relationship to structure of
the enzyme. Arthritis Rheum. 42,
1140–1146. doi: 10.1002/1529-
0131(199906)42:6<1140::AID-
ANR10>3.0.CO;2-7
Soczynska, J. K., Mansur, R. B., Bri-
etzke, E., Swardfager, W., Kennedy,
S. H., Woldeyohannes, H. O.,
et al. (2012). Novel therapeutic
targets in depression: minocycline
as a candidate treatment. Behav.
Brain Res. 235, 302–317. doi:
10.1016/j.bbr.2012.07.026
Sondheimer, I., and Knackstedt, L.
A. (2011). Ceftriaxone prevents the
induction of cocaine sensitization
and produces enduring attenuation
of cue- and cocaine-primed rein-
statement of cocaine-seeking. Behav.
Brain Res. 225, 252–258. doi:
10.1016/j.bbr.2011.07.041
Sperandio, V., Torres, A. G., Jarvis, B.,
Nataro, J. P., and Kaper, J. B. (2003).
Bacteria-host communication: the
language of hormones. Proc. Natl.
Acad. Sci. U.S.A. 100, 8951–8956. doi:
10.1073/pnas.1537100100
Spinale, F. G., Janicki, J. S., and Zile,
M. R. (2013). Membrane-associated
matrix proteolysis and heart fail-
ure. Circ. Res. 112, 195–208. doi:
10.1161/CIRCRESAHA.112.266882
Steadman, E., Raisch, D. W., Bennett,
C. L., Esterly, J. S., Becker, T., Postel-
nick,M., et al. (2010). Evaluation of a
potential clinical interaction between
ceftriaxone and calcium. Antimicrob.
Agents Chemother. 54, 1534–1540.
doi: 10.1128/AAC.01111-09
Stokstad, E. L. R., and Jukes, T. H.
(1950). Further observations of the
“animal protein factor”. Exp. Biol.
Med. 72, 523–528.
Strachan, D. P. (1989). Hay fever,
hygiene, and household size. BMJ
299, 1259–1260. doi: 10.1136/
bmj.299.6710.1259
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy August 2013 | Volume 4 | Article 241 | 14
“fmicb-04-00241” — 2013/8/16 — 21:17 — page 15 — #15
Aminov Biotic acts of antibiotics
Sugimoto, T., Tanikawa, T., Suzuki,
K., and Yamasaki, Y. (2012).
Synthesis and structure-activity
relationship of a novel class of 15-
membered macrolide antibiotics
known as ‘11a-azalides’. Bioorg.
Med. Chem. 20, 5787–5801. doi:
10.1016/j.bmc.2012.08.007
Suresh Babu, K., Kastelik, J., and Mor-
jaria, J. B. (2013). Role of long-term
antibiotics in chronic respiratory dis-
eases. Respir. Med. 107, 800–815. doi:
10.1016/j.rmed.2013.02.009
Suzuki, J., Ogawa, M., Hishikari,
K., Watanabe, R., Takayama, K.,
Hirata, Y., et al. (2012). Novel effects
of macrolide antibiotics on cardio-
vascular diseases. Cardiovasc. Ther.
30, 301–307. doi: 10.1111/j.1755-
5922.2011.00303.x
Suzuki, H., Sugimura, Y., Iwama,
S., Suzuki, H., Nobuaki, O.,
Nagasaki, H., et al. (2010). Minocy-
cline prevents osmotic demyelina-
tion syndrome by inhibiting the
activation of microglia. J. Am.
Soc. Nephrol. 21, 2090–2098. doi:
10.1681/ASN.2010040438
Syed, S., Takimoto, C., Hidalgo, M.,
Rizzo, J., Kuhn, J. G., Hammond, L.
A., et al. (2004). A phase I and phar-
macokinetic study of Col-3 (Meta-
stat), an oral tetracycline deriva-
tive with potent matrix metallopro-
teinase and antitumor properties.
Clin. Cancer Res. 10, 6512–6521. doi:
10.1158/1078-0432.CCR-04-0804
Tamaoki, J., Kadota, J., and Takizawa,
H. (2004). Clinical implications of
the immunomodulatory effects of
macrolides. Am. J. Med. 117(Suppl.
9A), 5S–11S.
Tamaoki, J., Takeyama, K., Tagaya,
E., and Konno, K. (1995). Effect
of clarithromycin on sputum
production and its rheological
properties in chronic respiratory
tract infections. Antimicrob. Agents
Chemother. 39, 1688–1690. doi:
10.1128/AAC.39.8.1688
Tarran, R., Sabater, J. R., Clarke, T.
C., Tan, C. D., Davies, C. M.,
Liu, J., et al. (2013). Nonantibi-
otic macrolides prevent human neu-
trophil elastase-induced mucus sta-
sis and airway surface liquid volume
depletion. Am. J. Physiol. Lung. Cell.
Mol. Physiol. 304, L746–L756. doi:
10.1152/ajplung.00292.2012
Tateda, K., Ishii, Y., Kimura, S.,
Horikawa, M., Miyairi, S., and
Yamaguchi, K. (2007). Suppression
of Pseudomonas aeruginosa quorum-
sensing systems by macrolides: a
promising strategy or an oriental
mystery? J. Infect. Chemother. 13,
357–367. doi: 10.1007/s10156-007-
0555-2
Thomas, P. J., Qu, B. H., and Peder-
sen, P. L. (1995). Defective protein
folding as a basis of human dis-
ease. Trends Biochem. Sci. 20, 456–
459. doi: 10.1016/S0968-0004(00)
89100-8
Thöne-Reineke, C., Neumann, C.,
Namsolleck, P., Schmerbach, K.,
Krikov, M., Schefe, J. H., et al.
(2008). The beta-lactam antibiotic,
ceftriaxone, dramatically improves
survival, increases glutamate uptake
and induces neurotrophins in stroke.
J. Hypertens. 26, 2426–2435. doi:
10.1097/HJH.0b013e328313e403
Tikka, T. M., Fiebich, B. L., Goldsteins,
G., Keinanen, R., and Koistinaho, J.
(2001). Minocycline, a tetracycline
derivative, is neuroprotective against
excitotoxicity by inhibiting activa-
tion and proliferation of microglia. J.
Neurosci. 21, 2580–2588.
Tikka, T. M., Vartiainen, N. E., Gold-
steins, G., Oja, S. S., Andersen, P.
M., Marklund, S. L., et al. (2002).
Minocycline prevents neurotoxicity
induced by cerebrospinal ﬂuid from
patients with motor neurone dis-
ease. Brain 125, 722–731. doi:
10.1093/brain/awf068
Trantham-Davidson, H., LaLumiere, R.
T., Reissner, K. J., Kalivas, P. W., and
Knackstedt, L. A. (2012). Ceftriax-
one normalizes nucleus accumbens
synaptic transmission, glutamate
transport, and export following
cocaine self-administration and
extinction training. J. Neurosci.
32, 12406–12410. doi: 10.1523/
JNEUROSCI.1976-12.2012
Unemo, M., and Nicholas, R. A.
(2012). Emergence of multidrug-
resistant, extensively drug-resistant
and untreatable gonorrhoea. Future
Microbiol. 7, 1401–1422. doi:
10.2217/fmb.12.117
Vasseur, S., Hoffmeister, A., Garcia,
S., Bagnis, C., Dagorn, J. C., and
Iovanna, J. L. (2002). p8 is criti-
cal for tumour development induced
by rasV12 mutated protein and E1A
oncogene. EMBO Rep. 3, 165–170.
doi: 10.1093/embo-reports/kvf023
Verma, R., Mishra, V., Sasmal, D.,
and Raghubir, R. (2010). Phar-
macological evaluation of gluta-
mate transporter 1 (GLT-1) medi-
ated neuroprotection following cere-
bral ischemia/reperfusion injury. Eur.
J. Pharmacol. 638, 65–71. doi:
10.1016/j.ejphar.2010.04.021
Vézina, C., Kudelski, A., and Sehgal, S.
N. (1975). Rapamycin (AY-22,989), a
new antifungal antibiotic. I. Taxon-
omy of the producing streptomycete
and isolation of the active principle.
J Antibiot. (Tokyo) 28, 721–726. doi:
10.7164/antibiotics.28.721
Wain, L.V., SolerArtigas,M., and Tobin,
M. D. (2012). What can genetics
tell us about the cause of ﬁxed air-
ﬂow obstruction? Clin. Exp. Allergy
42, 1176–1182. doi: 10.1111/j.1365-
2222.2012.03967.x
Wang, X., Zhu, S., Drozda, M.,
Zhang, W., Stavrovskaya, I. G., Cat-
taneo, E., et al. (2003). Minocy-
cline inhibits caspase-independent
and -dependent mitochondrial cell
death pathways in models of Hunt-
ington’s disease. Proc. Natl. Acad.
Sci. U.S.A. 100, 10483–10487. doi:
10.1073/pnas.1832501100
Watabe, M., Kato, T. A., Tsuboi,
S., Ishikawa, K., Hashiya, K.,
Monji, A., et al. (2013). Minocy-
cline, a microglial inhibitor, reduces
’honey trap’ risk in human economic
exchange. Sci. Rep. 3, 1685. doi:
10.1038/srep01685
Webster, G., and Del Rosso, J. Q. (2007).
Anti-inﬂammatory activity of tetra-
cyclines. Dermatol. Clin. 25, 133–135.
doi: 10.1016/j.det.2007.01.012
Wei, J., Pan, X., Pei, Z., Wang,
W., Qiu, W., Shi, Z., et al.
(2012). The beta-lactam antibiotic,
ceftriaxone, provides neuroprotec-
tive potential via anti-excitotoxicity
and anti-inﬂammation response in
a rat model of traumatic brain
injury. J. Trauma Acute Care Surg.
73, 654–660. doi: 10.1097/TA.0b013
e31825133c0
Weinberg, J. M. (2005). The anti-
inﬂammatory effects of tetracyclines.
Cutis 75, 6–11.
Wiederrecht, G. J., Sabers, C. J., Brunn,
G. J., Martin, M. M., Dumont,
F. J., and Abraham, R. T. (1995).
Mechanism of action of rapamycin:
new insights into the regulation of
G1-phase progression in eukaryotic
cells. Prog. Cell Cycle Res. 1, 53–
71. doi: 10.1007/978-1-4615-1809-
9_5
Won, S. J., Kim, J. H., Yoo, B.
H., Sohn, M., Kauppinen, T.
M., Park, M. S., et al. (2012).
Prevention of hypoglycemia-induced
neuronal death by minocycline. J.
Neuroinﬂammation 9, 225. doi:
10.1186/1742-2094-9-225
Wong, R., Beguelin, G. Z., de Lima, M.,
Giralt, S. A., Hosing, C., Ippoliti, C.,
et al. (2003). Tacrolimus-associated
posterior reversible encephalopa-
thy syndrome after allogeneic
haematopoietic stem cell transplan-
tation. Br. J. Haematol. 122, 128–134.
doi: 10.1046/j.1365-2141.2003.
04447.x
Wright, A. J., Gomes, T., Mamdani,
M. M., Horn, J. R., and Juurlink, D.
N. (2011). The risk of hypoten-
sion following co-prescription
of macrolide antibiotics and
calcium-channel blockers. CMAJ
183, 303–307. doi: 10.1503/cmaj.
100702
Wu, D. C., Jackson-Lewis, V., Vila, M.,
Tieu, K., Teismann, P., Vadseth, C.,
et al. (2002). Blockade of microglial
activation is neuroprotective in
the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine mouse model
of Parkinson disease. J. Neurosci. 22,
1763–1771.
Wu, Q., Marescaux, C., Wolff, V.,
Jeung, M. Y., Kessler, R., Lauer, V.,
et al. (2010). Tacrolimus-associated
posterior reversible encephalopathy
syndrome after solid organ trans-
plantation. Eur. Neurol. 64, 169–177.
doi: 10.1159/000319032
Wullschleger, S., Loewith, R., and
Hall, M. N. (2006). TOR sig-
naling in growth and metabolism.
Cell 124, 471–484. doi: 10.1016/
j.cell.2006.01.016
Yim, G., Wang, H. H., and Davies, J.
(2006). The truth about antibiotics.
Int. J. Med. Microbiol. 296, 163–170.
doi: 10.1016/j.ijmm.2006.01.039
Yim, G., Wang, H. H., and Davies,
J. (2007). Antibiotics as signalling
molecules. Philos. Trans. R. Soc. Lond.
B Biol. Sci. 362, 1195–1200. doi:
10.1098/rstb.2007.2044
Yrjanheikki, J., Keinanen, R., Pel-
likka, M., Hokfelt, T., and
Koisinaho, J. (1998). Tetracy-
clines inhibit microglial activation
and are neuroprotective in global
brain ischemia. Proc. Natl. Acad.
Sci. U.S.A. 95, 15769–15774. doi:
10.1073/pnas.95.26.15769
Yrjanheikki, J., Tikka, T., Keina-
nen, R., Goldsteins, G., Chan, P.
H., and Koistinaho, J. (1999). A
tetracycline derivative, minocycline,
reduces inﬂammation and protects
against focal cerebral ischemia with
a wide therapeutic window. Proc.
Natl. Acad. Sci. U.S.A. 96, 13496–
13500. doi: 10.1073/pnas.96.23.
13496
Yuhas, Y., Berent, E., Cohen, R.,
and Ashkenazi, S. (2009). Role of
NF-kappaB activation and peroxi-
some proliferator-activated receptor
gamma inhibition in the effect of
rifampin on inducible nitric oxide
synthase transcription in human lung
epithelial cells. Antimicrob. Agents
Chemother. 53, 1539–1545. doi:
10.1128/AAC.00961-08
Zabad, R. K., Metz, L. M., Todoruk,
T. R., Zhang, Y., Mitchell, J. R.,
Yeung, M., et al. (2007). The clinical
response to minocycline in multiple
sclerosis is accompanied by beneﬁcial
immune changes: a pilot study. Mult.
Scler. 13, 517–526.
www.frontiersin.org August 2013 | Volume 4 | Article 241 | 15
“fmicb-04-00241” — 2013/8/16 — 21:17 — page 16 — #16
Aminov Biotic acts of antibiotics
Zhao, L., Xu, J., Yang, Y., Chong, Y., Liu,
C., Jiao, Y., et al. (2013a). Inhibitory
impacts of chemically modiﬁed
tetracycline-3 and underlying mech-
anism in human cervical cancer cells.
Anticancer Drugs 24, 799–809. doi:
10.1097/CAD.0b013e328362b1be
Zhao, Y., Wu, J., Li, J. V., Zhou, N.
Y., Tang, H., and Wang, Y. (2013b).
Gut microbiota composition modi-
ﬁes faecal metabolic proﬁles in mice.
J. Proteome Res. 12, 2987–2999. doi:
10.1021/pr400263n
Zhu, S., Stavrovskaya, I. G., Drozda,
M., Kim, B. Y., Ona, V., Li, M.,
et al. (2002). Minocycline inhibits
cytochrome c release and delays pro-
gression of amyotrophic lateral scle-
rosis in mice. Nature 417, 74–78. doi:
10.1038/417074a
Conflict of Interest Statement: The
author declares that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 07 July 2013; paper pending
published: 27 July 2013; accepted: 31 July
2013; published online: 19 August 2013.
Citation: Aminov RI (2013) Biotic acts of
antibiotics. Front. Microbiol. 4:241. doi:
10.3389/fmicb.2013.00241
This article was submitted to Anti-
microbials, Resistance and Chemother-
apy, a section of the journal Frontiers in
Microbiology.
Copyright © 2013 Aminov. This is
an open-access article distributed under
the terms of the Creative Commons
Attribution License (CC BY). The use,
distribution or reproduction in other
forums is permitted, provided the orig-
inal author(s) or licensor are credited
and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permit-
ted which does not comply with these
terms.
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy August 2013 | Volume 4 | Article 241 | 16
